Patent Publication Number: US-2018051334-A1

Title: Method for Studying V(D)J Combinatory Diversity

Description:
The present invention relates to the immunology field. More specifically, the present invention relates to a method for the in vitro analysis of the diversity of the T and/or B lymphocyte repertoire of an individual and to uses thereof, in particular in the follow-up of a treatment or in the diagnosis and/or prognosis of certain pathological conditions. 
    
    
     
       BRIEF DESCRIPTION OF DRAWINGS 
         FIG. 1A  depicts a schematic representation of TRAD locus. 
         FIG. 1B  represents a multi-N-plex PCR amplification of VJ rearrangements. Primers allow the amplifications of fragments of different sizes based on the V and J gene rearranged. These fragments are then discriminated by electrophoresis analysis which allows their identification based on the expected sizes. 
         FIG. 2A  depicts an analysis of the average GC content of the human TRBJ and TRAJ regions. The J2 region contains a very high GC content, with 60% against 40-45% on average. 
         FIG. 2B  represents a particular arrangement of the J genes and primers of the TRB locus (in 2 distinct clusters). 
         FIG. 2C  is an illustration of the principle for choosing the primers, with one antisense primer close to a J cluster and a second antisense primer far from the J cluster, making it possible to position the entire J1 cluster above the J2 cluster. 
         FIG. 2D  depicts an example of a result obtained electrophoresis of fragments obtained by multi-N-plex PCR. 
         FIG. 3  represents an analysis by multi-N-plex PCR of several loci in the same reaction discriminated by agarose gel electrophoresis. Rearrangements of the TCRB and TCRD repertoires are observed in a single step. 
         FIGS. 4A-4E  are illustrations of the principle of “embedded” multi-n-plex PCR, i.e. in which the series of amplicons obtained with the various pairs of primers are such that an amplicon obtained with a first pair of primers can be bordered by 2 amplicons obtained with a second pair of primers. 
         FIG. 4A  is a representation of the TRG locus. 
         FIG. 4B  is an in silico representation of hTRGV family resolution by gel electrophoresis. 
         FIG. 4C  represents a multiplex PCR on the hTRG locus, targeting the 2 J clusters with a single J primer. The experiment was carried out on HEK and CaCO cells as negative controls (upper gel) and on PBMCs and thymus cells as positive controls (lower gel). 
         FIG. 4D  shows an example of embedded multi-2-plex PCR with two TRAJ primers. 
         FIG. 4E  shows an example of resolution of 95% of the AJ region with only 6 multi-2-plex PCRs. The position of the primers is indicated below the name of the J gene of the oligonucleotides downstream of the (start of the) J gene. 
         FIG. 5  is a diagrammatic representation of the theoretical result obtained with the human TRB ImmunTraCkeR kit (the representation is similar in other species: rat, mouse, monkey, etc.). Each column corresponds to one TRBV family, each band corresponds to a given V-J rearrangement. The TRBV genes were studied in the following order: BV2, BV3, BV4, BV5, BV6, BV7, BV9, BV10, BV11, BV12, BV13, BV14, BV15, BV16, BV18, BV19, BV20, BV24, BV25, BV27, BV28, BV29, BV30. 
         FIG. 6  represents the experimental results of multi-N-plex PCR obtained in duplicate (loaded side by side) with three types of samples: gDNA extracted from thymus, gDNA extracted from PBMCs under lymphopenic conditions and, finally, a pool of DNA of 4 T lines each comprising one or two TRBV-J rearrangements. 
         FIGS. 7A-7B  show the results of a test for detecting incomplete D-Jβ rearrangements. (lanes A: D1 rearrangements with the J1 cluster and the J2 cluster. Lanes B: D2 rearrangements with the J2 cluster). 
         FIG. 8A  shows a synthetic table of all the data from analysis of the immune repertoire, including in particular the count, and/or the diversity of the sample, and/or the intensity of the signal, and/or a comparison with a reference diversity originating from another patient or from the same patient, information for identifying that the patient is suffering from lymphopenia by comparing the % diversity obtained with a reference repertoire, and/or information on the number of clones detected in the image. 
         FIG. 8B  depicts a three-dimensional representation of each observed VJ rearrangement. X and Y coordinates allow the identification of a VJ rearrangement while Z axis gives the frequency of each rearrangement. 
         FIG. 8C  shows a two-dimensional representation of each observed VJ rearrangement. X and Y coordinates allow the identification of a VJ rearrangement. 
         FIG. 8D  represents a list of all the V-J rearrangements classified by a decreasing amount of amount of signal detected, and % representativeness in the image. 
         FIG. 9  shows absolute lymphocyte count as a function of combinatorial diversity (LCD). Several zones are identified with associated risk. 
         FIG. 10  shows a decision tree in oncology-hematology using LCD. 
         FIG. 11  is a “SADZ” representation that allows the comparison of two immune repertoires in order to identify the similarities or differences that may exist. The region S for “stable” represents the number of rearrangements observed in the two samples. The zone A for “appeared” represents the number of rearrangements observed in sample 2 but not in sample 1. The zone D for “disappeared” represents the number of rearrangements which are observed in sample 1 but not in sample 2. Finally, the zone Z for “never seen” represents the number of rearrangements which are observed neither in sample 1 nor in sample 2. 
         FIG. 12A  shows ImmunTraCkeR analysis on thymus sample by gel electrophoresis (upper picture) and monitored by real time PCR (lower graphic). Each curve corresponds to a V family. 
         FIG. 12B  shows ImmunTraCkeR analysis on a pool of three cell lines by gel electrophoresis (upper picture) and monitored by real time PCR (lower graphic). Each curve corresponds to a V family. 
         FIG. 12C  shows ImmunTraCkeR&#39;s illustration of qPCR parameters behaviours in a clonal context. Red line represent a clonal repertoire and green a diversified repertoire.
         A. Example of clonal proliferation highlighted by Cp.   B. Example of clonal proliferation highlighted by melting curve.   C. Example of clonal proliferation highlighted by Cot analysis (molecular diversity)   D. Three dimension map of ImmunTraCkeR test. Upper map correspond to a clonal repertoire. Lower map correspond to a diversified repertoire.   E. Three dimensional graphic summarizing the count as a function of the combinatorial and molecular diversity (cot analysis).       

         FIG. 13  depicts examples of analysis of the IgH and TCR repertoires at various times, in order to monitor the change in these repertoires in two patients, in response to a treatment. 
         FIG. 14  shows a three-dimensional representation of the LCD (lymphocyte count/diversity). This graph groups together the measurement of diversity of the B lymphocytes and T lymphocytes, and also the count, as % or as absolute value, of the number of lymphocytes present in the sample. 
         FIG. 15  is a diagrammatic form of the application of the method of the invention to the monitoring of the reconstitution of the immune repertoire in a patient having undergone a stem cell (marrow) transplant. 
         FIG. 16  shows four mappings that illustrate steps 5 and 6 of the previous figure. The four mappings represent the diversity of the immune repertoire measured using samples from the same patient at two times before the treatment (approximately 200 and 250 days), and two times post-treatment (approximately 300 and 600 days). The results concerning these four samples are represented in a graphic according to the intensity, the count and the diversity. 
         FIG. 17  depicts the comparison of rearrangements contribution by V family in human repertoire (left graphic), a mouse model with a good reconstitution (middle graphic) and a partial reconstitution in the same mouse model (right graphic). 
         FIG. 18  is an LCD (lymphocyte count/diversity) representation of the evaluation of the effectiveness of an epitope (an antigen) in the case of the development of a treatment (vaccine), by measuring the decrease in diversity of the immune repertoire of a sample containing T lymphocytes.
         A. The epitope tested results in a considerable lymphocyte selection, as indicated by the decrease in the diversity.   B. The epitope tested is not very selective, as can be observed by comparison with a negative control.   C. Negative control.       

         FIG. 19  shows the summary of the results describing the comparison of three techniques for immunomonitoring of the immune cell repertoires: Tonotest, ImmunTraCker and Biomed-2. 
         FIG. 20  is a diagram of the steps for carrying out the test. 
         FIG. 21  shows the example of three control sample types systematically used for the validation of production batch. From top to bottom: a thymus immune repertoire (polyclonality), an immune repertoire when the sample comprises only one very predominant clone (clonality) and, finally, an immune repertoire when the sample comprises several clones (oligoclonality). 
         FIG. 22A  is a diagram of qPCR results in three separate situations: healthy (as regards the condition of said patient&#39;s immune system), lymphoproliferation or lymphopenia. 
         FIG. 22B  is a summary diagram of the three situations. N.B. other than for the control gene (in this example, the Actin gene), each curve corresponds to the PCR amplification of the sum of the rearrangements of a given V gene with all the J genes monitored. 
         FIG. 23  is a graph of the number of regulatory T lymphocytes as a function of the immunity diversity of the T lymphocytes. Each point corresponds to an individual (the individuals in this example being mice). The graph shows three groups of individuals: A/before vaccination or injection of PBS (=negative control), B/after vaccination with vaccination protocol n°1, C/after vaccination with vaccination protocol n°2. 
         FIGS. 24A and 24B  show immunological status (analyzed through LCD) of two immunosuppressed patients ( 24   a  &amp;  24   b ) during the reconstitution of their immune repertoire. Vectors (green and red arrow) indicate the evolution of the patient between each time point. 
         FIG. 25  depicts a summary in a three dimensional LCD graph of the two examples seen in  FIGS. 24A and 24B . This graph groups together the measurement of diversity of the B lymphocytes and T lymphocytes, and also the count, as % or as absolute value, of the number of lymphocytes present in the sample. 
         FIG. 26  shows an example of follow-up with LCD of 21 patients receiving a treatment. This graph groups together the measurement of diversity of the B lymphocytes and T lymphocytes, and also the count, as % or as absolute value, of the number of lymphocytes present in the sample. 
         FIGS. 27A-27G  depict the individual evolution of 5 different patients in LCD graph. The occurrence of a febrile and/or infectious event is indicated by a Roman numeral corresponding to the grade of the infection. The higher the grade, the more serious the infection. 
     
    
    
     In order to be functional, a lymphocyte must have an antigen-specific recognition system. This parameter is essential: it defines the very function of the T or B cell. During the early stages of T-lymphocyte differentiation, the loci encoding the clonotypic chains of the TCR receptor undergo rearrangements so as to allow the expression of a functional receptor. Similarly, in B lymphocytes, the loci encoding the immunoglobulin (Ig) chains undergo rearrangements so as to allow the expression of a functional Ig. 
     The mechanism of V(D)J rearrangement is specific to T and B lymphocytes. The V, D and J genes encoding the TCR are distributed over long germinal portions within the various TCR loci. To give a protein, these genes must be associated in an exon by means of a gene rearrangement process, called V(D)J recombination. The principle of the recombination is based on the recognition of RSS sequences specific for the V(D)J genes, and the excision of the chromosomal region intercalated between the two rearranged genes. Each V and J gene has, at one of its ends, a recombination signal sequence (RSS). As for the D genes, they have them at both ends. RSSs are sequences recognized by the specific recombinase enzymes RAG I and RAG II, expressed specifically in lymphocytes. These proteins are the main players of rearrangement. Once associated with the HMG (high mobility group) proteins, the RAG enzymes recognize the RSS nonamer by virtue of their homeodomain and induce cleavage between the V, D, J gene segment and the heptamer, so as to generate a coding end and a signal end. Rearrangement is completed after ligation of the two V and J coding ends. This step is preceded by the action of the TdT enzyme and of a nuclease at the V-J junction. Once rearranged, the neoformed gene is transcribed and then spliced to give mRNA before being translated into a membrane protein. 
     A given TCR specifically recognizes a limited number of different antigenic peptides. Consequently, a vast repertoire of receptors is required in order to provide the individual&#39;s defense against the multiple infections that the latter may encounter in his or her environment. For this, the immune system has developed a mechanism of assembly of a large number of V, D, J gene segments positioned discontinuously in the genome. This “assembly” mechanism, called V(D)J recombination, is independent from one cell to the other and makes it possible to obtain a single “fragment” of gene encoding the TCR. This system makes it possible, with a modest number of genes, to generate a large number of different receptors. Each cell uses a combination of gene segments according to precise rules and obtains a potentially unique TCR chain. 
     Four major mechanisms contribute to generating the diversity of the repertoire: 1) a combinatorial diversity which corresponds to the first step of rearrangement between a V segment (a D segment) and a J segment; 2) a junctional diversity, generated at the junction between the rearranged gene segments; 3) somatic hypermutations in the rearranged V-J and V-D-J genes; 4) a diversity of pairing of the protein hetero-dimers TCRα×TCRβ or TCRγ×TCRδ. 
     The first step for generating diversity is based on the principle of V(D)J gene rearrangement ( FIGS. 1A-1B ). The combinations resulting from the pairing of a fixed number of V, D and J genes form the combinatorial diversity. The calculation of this diversity consists in estimating the number of possible combinations mV×nD×pJ. The mechanism regulating V(D)J recombination is not random: it is spatiotemporally regulated during ontogenesis (Aude-Garcia et al., 2001; Jouvin-Marche et al., 1998; Pasqual et al., 2002; Rytkonen et al., 1996) Simple multiplication is not therefore sufficient. to estimate the total number of expected gene combinations. This first step for generating diversity defines the order of magnitude of the repertoire. This is because, even if this step generates only a modest combination variability (of the order of a few thousand possible combinations compared with the maximum theoretical repertoire estimated at 
     10 15  (Davis and Bjorkman, 1988)), the maximum combinatorial diversity is directly linked to the number of V, D and J genes initially available: the other two steps for generating diversity exponentially amplify the diversity of the primary repertoire. 
     Junction diversity makes it possible to generate a very large variability at the level of the CDR3 region of the receptor in contact with the antigenic peptide. Two mechanisms contribute to increasing the junctional diversity: 1) the first mechanism is due to the addition of P (for palindromic) nucleotides, originating from the resolution of the hairpin of the rearranged segments (Fugmann et al., 2000). The diversity generated is not as great as that originating from the second mechanism involving the terminal deoxy-nucleotidyl transferase enzyme; 2) TdT produces a substantial diversity, by randomly adding N nucleotides at the 3′ end of each coding segment, without the need for a genomic template (Bogue et al., 1992). Studies on the TdT −/− mouse have made it possible to estimate that, in these animals, the TCRαβ repertoire represents only 5% to 10% of the normal repertoire and therefore that TdT is responsible for 90% of the generation of the total diversity of TCRαβ. In addition, these results have shown that the length of the CDR3s in the TCRβ transcripts are clearly reduced, unlike the CDR3 of the TCRα transcripts. This observation verifies, as expected, a greater contribution of TdT to V-D-J recombinations than to V-J rearrangements (Cabaniols et al., 2001). 
     The mechanism of secondary rearrangements contributes to “conserving” diversity: the junctional diversity represents the greatest factor of amplification of the diversity of the repertoire, but if there was not the mechanism of secondary rearrangement for saving ⅔ of the thymocytes having interrupted their reading frame, this benefit in terms of diversity would represent a considerable cost for the organism, even before the positive selection step. These nonproductive rearrangements cannot give a functional TCR protein. The cell then has the possibility of attempting a second rearrangement with the V(D)J genes still available on the locus. The property of concentric opening of the TRAD locus promotes this process, leaving the cell with the most possible chances, since the first rearrangements carried out by the cell take place between a pair of V-J genes close to one another (Huang and Kanagawa, 2001; Pasqual et al., 2002; Wang et al., 1998). If these first rearrangements are not productive, the cell has the possibility of attempting rearrangements on its second chromosome, or else of using the V and J genes available on either side of the first rearrangement. Thus, the secondary rearrangements allow the survival of a large number of cells which, at the end of a first nonproductive rearrangement, should have been eliminated. 
     Somatic hypermutations (SHMs) take place during B lymphocyte differentiation in the lymph nodes, when an antigen is encountered (Berek et al., 1985). The SHMs are located in “hot spot motifs” of the rearranged V-J and V(D)J genes of Igs (Chaudhuri et al., 2003; Oprea and Kepler, 1999), but also, in certain cases, in rearranged V-J and V(D)J genes of TCRs (Kotani et al., 2005). The TCR can be the target of SHMs in the variable genes, if the lymphocyte overexpresses the AID (activation-induced cytidine diaminase) enzyme which is normally specific for B lymphocytes. Under normal circumstances, the TCR does not undergo SHM since the T lymphocyte quite simply does not synthesize AID. Nevertheless, if the T lymphocyte starts to express it, the TCR is as sensitive to this enzyme as the BCR since it possesses all the sequence on which it acts. Overall, it is described in the literature that this mechanism induces an additional diversity by a factor of 1000 with the objective of increasing the chances of recognizing an antigen. 
     The diversity derived from the pairing between a TCRα chain and a TCRβ chain can be estimated by multiplying the number of different combinations of a TCRα chain by the number of possible combinations for the TCRβ chain. The diversity generated by this mechanism is directly dependent on the number of primary combinations that is obtained during the rearrangement. Specifically, if one examines the number of primary TCRγδ combinations in the mouse, without taking into account the junctional diversity, the result is only 40 TCRδ (=10V*2D*2J)×28 TCRγ (=7V*4J)=1120 different combinations, whereas the same calculation gives 5.6×10 6  combinations for TCRαβ (calculated as follows: 102Vα*60Jα*33Vβ*2Dβ*14Jβ). 
     Complete sequencing of the human genome and of the mouse has recently made it possible to obtain the definitive maps of each of the TCR loci and consequently makes possible new genetic approaches for discovering the mechanisms of regulating recombination. Each cell has 4 loci capable of rearranging TCR genes. In humans and mice, the TCRα and TCRδ chains are rearranged in two associated loci on the same chromosome 14. The human TCRγ and TCRβ loci are on chromosomes 7 (or 13 in the mouse) and 7 (or 6 in the mouse), respectively (see table 1). 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Comparative table of the principal known characteristics of the 4 loci in humans and BALB/c 
               
               
                 mice (according to the IMGT data, MP Lefranc). 
               
            
           
           
               
               
               
               
               
            
               
                 Chain 
                 TCRα 
                 TCRδ 
                 TCRβ 
                 TCRγ 
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                 Species 
                 Human 
                 Mouse 
                 Human 
                 Mouse 
                 Human 
                 Mouse 
                 Human 
                 Mouse 
               
               
                   
               
               
                 Chromosome 
                 14q11.2 
                 14c1 
                 14q11.2 
                 14c1 
                 7q34 
                 6A-C 
                 7p14 
                 13A2-3 
               
               
                 Locus size 
                 1000 Kb 
                 1500 Kb 
                 1000 Kb 
                 1500 Kb 
                 620 Kb 
                 700 Kb 
                 160 Kb 
                 20 Kb 
               
               
                 Number of V 
                 54 
                 102 
                 6 + nVa 
                 10 + nVa 
                 63-67 
                 33 
                 12-15 
                 7 
               
               
                 genes 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Number of V 
                 41 
                 23 
                 6 + nVa 
                 10 + nVa 
                 30 
                 30 
                 6 
                 7 
               
               
                 families 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Number of D 
                 — 
                 — 
                 3 
                 2 
                 2 
                 2 
                 — 
                 — 
               
               
                 genes 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Number of J 
                 61 
                 60 
                 4 
                 2 
                 6 + 7 
                 7 + 7 
                 5 
                 4 
               
               
                 genes 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Number of C 
                 1 
                 1 
                 1 
                 1 
                 2 
                 2 
                 2 
                 4 
               
               
                 genes 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Number of 
                 8 
                 15 
                 0 
                 0 
                 12-13 
                 13 
                   
                 — 
               
               
                 pseudo V 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 transcription 
                 — 
                 — 
                 0 
                 0 
                 — 
                 — 
                   
                 — 
               
               
                 rearrangement 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Number of 
                 8 
                 6 
                 0 
                 0 
                 2 
                 — 
                 0 
                 — 
               
               
                 pseudo J 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 transcription 
                 8 
                 16 
                 0 
                 0 
                 2 
                 2 
                 0 
                 — 
               
               
                 rearrangement 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 (P-R) 
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 Maximum 
                 54V* (61 
                 102V* (6 
                 6V*3D*4 
                 10V*2D* 
                 (67V*D1*6J1 
                 (33V*D1*7J1- 
                 15*5 =  
                 7*4 = 28 
               
               
                 combinatorial 
                 J-8PR) =  
                 OJ- 
                 J = 72 
                 2J = 40 
                 *2C) + (67*D1* (8J2-2PR)* 
                 PR*2C) + (33*D1* (7J2- 
                 75 
                   
               
               
                 V (D) J without 
                 2915 
                 16PR) =  
                   
                   
                 C1 + 67*D2* (8J2- 
                 1PR)* (C1 + 33*D2* (7J2- 
                   
                   
               
               
                 P-R 
                   
                 4488 
                   
                   
                 2PR) *C2 = 804 + 402 + 402 =  
                 1PR) *C2 =  
                   
                   
               
               
                   
                   
                   
                   
                   
                 1608 
                 396 + 198 + 198 = 792 
                   
                   
               
               
                   
               
            
           
         
       
     
     Observation #1: the dashes (−) indicate the absence of exhaustive studies for counting with certainty the number of rearrangement pseudogenes. 
     Observation #2: estimation of the TCRβ combinations. According to the structure of the TCRβ locus in humans, the genes rearranged on the D1 segment can rearrange on the J1.1-J1.6 segments and are then spliced with BC1 or BC2. They can also rearrange on the second set of segments J2.1-J2.8, but are then only spliced on BC2. If it is the D2 segment that is used, only the set J2.1 to J2.8 can be used, and the splicing will take place on the BC2 chain. This results in a combinatorial diversity that is fractionated according to the D1 or D2 segment chosen during the D-J rearrangement: (67V*1D1*6J1*2BC)+(67*1D1*(8J2−2PR)*1BC1)+67*1D2*(8J2−2PR)*1BC2=1608 possible combinations. 
     V(D)J gene nomenclature has changed several times over the past few years. The name of the genes, which was first of all assigned according to the order in which they were discovered, is now defined as a function of their position in the locus. The latest nomenclature is that of IMGT (http://imgt.cines.fr), which arranges the V families logically with respect to one another and intuitively classifies the members of a family on the locus. This IMGT nomenclature implies that all the V genes are known. The TRAV1 gene is the furthest from the AJ segments. It is the most upstream (on the 5′ side) gene of the V region. The closer one gets to the J region, the higher the V-family number: thus, the human TRAV41 family is the closest to the AJ region. The members of a family have a name made up of the number of the family and then the number of the member. For example, TRAV8.1 is the most upstream (5′) member of the TRAV8 family, whereas the TRAV8.6 member is the most downstream (3′) on the V region. In the subsequent text, the IMGT nomenclature is used. 
     The diversity of the repertoire of immunoglobulins produced by B lymphocytes is the result of the same mechanisms as those described above for T lymphocytes. 
     Measurement of the immunological diversity makes it possible, inter alia, to study the mechanisms for setting up the immune repertoire, homeostasis, the T or B lymphocytes involved in an immune response, or in a leukemia, or else to evaluate the immunodeficiency induced by a treatment or, conversely, the specific immune system activation. This list is not exhaustive. 
     The study of the immune repertoire of a lymphocyte population has led to the development of several multi-parametric approaches making it possible both to measure the degree of diversity and to identify the presence of certain specific T or B clones. Some approaches developed by immunologists for evaluating these various degrees of diversity are listed below according to the principle and the “degree” of diversity measured. 
     Measurement of V Diversity
         By cytometry (Van den Beemd, van Dongen et al. 2000).   By Q-PCR at the genomic and transcriptomal level (Fuschiotti et al., 2007; Lang et al., 1997; Pasqual et al., 2002).       

     Measurement of CDR3 Junctional Diversity:
         By Immunoscope® (Cochet et al., 1992; Pannetier et al., 1995).   By Q-PCR coupled to immunoscope (TcLandscape®).   By sequencing.   By the Amplicot method at the genomic level (Baum and McCune, 2006).   By DNA chip (Bonarius et al., 2006).       

     Study of Somatic Hypermutations (SHMs):
         By PCR/sequencing (Hamblin et al., 1999).       

     Indirect Measurement Via the Decrease in TREC Excision Circles
         By PCR (Douek et al., 1998).   By Q-PCR (Pham et al., 2003).       

     While some of these approaches have already proved their worth in fundamental research, in particular Immunoscope® (Pannetier, C., J. Even, et al., 1995) or flow cytometry (Van den Beemd, van Dongen et al., 2000), there still remains a certain number of scientific and technical validations to be provided in order to evaluate the relevance of the use thereof as a medical biomarker. Faced with the complexity of the immune system, the scientist would need to couple complementary technological approaches in order to decode all the information contained in the immune repertoire and relevant to a given pathological condition. 
     Other methods, based on the use of PCR specifically amplifying nucleic acid segments characteristic of certain rearrangements, have been described. 
     For example, patents U.S. Pat. No. 5,296,351 and U.S. Pat. No. 5,418,134 present a method for detecting lymphoid leukemias or B or T lymphomas, based on the amplification of sequences encoding immunoglobulins and/or T receptors, using “consensus” primers for simultaneously amplifying several V-J rearrangements. 
     Application WO2005/056828 describes a method based on the use of multiplex PCRs, which are polymerase chain reactions (PCRs) in which several different fragments, corresponding to different rearrangements, are amplified, with the same pair of primers, from genomic DNA. 
     However, none of the methods described above makes it possible to obtain, in a reasonable amount of time, resolution of the V(D)J rearrangements of the immune repertoire, nor even resolution of all the rearrangements that have occurred in a given locus. This is because the number of multiplex PCRs to be carried out for this would be too high for it to be possible to envision routine use of these methods. 
     The present invention is based on several improvements of the method described in application WO2005/056828, for enabling the analysis of a larger number of V(D)J rearrangements in a reliable, easy and rapid manner. Consequently, the methods of the present invention constitute tools of choice for analyzing the diversity of the repertoire of B and/or T lymphocytes in a sample in numerous applications, such as immunomonitoring in preclinical or clinical phases, for studying the effect of a treatment on the (re)constitution of the immune system, personalized diagnosis, prognosis, in particular in oncology-hematology, etc. 
     The present invention therefore relates, firstly, to a method for the in vitro analysis of the diversity of the repertoire of T and/or B lymphocytes in a human or animal individual, from genomic DNA originating from a biological sample from said individual, comprising the following steps: 
     A) amplification of fragments of said genomic DNA by multiplex PCRs, at least one of which is a multi-n-plex PCR with n≧2, carried out with a combination of at least 3 primers, constituting at least 2 pairs of primers having the following characteristics: 
     (i) each pair of primers is constituted of a primer which specifically hybridizes upstream of and/or in a given V or D gene and of a primer which specifically hybridizes downstream of and/or in a given J gene, so as to allow the amplification, with each pair of primers, of at least two fragments characteristic of two distinct V-J or D-J rearrangements; 
     (ii) the primers (i.e. all the primers used in the same amplification reaction) are thermodynamically compatible; 
     (iii) the primers are chosen in such a way that the fragments amplified with the first pair of primers can be distinguished from the fragments amplified with the second pair of primers; 
     B) detection of the amplification products obtained in step A); 
     C) interpretation of the results. 
     For the implementation of this method, the genomic DNA is preferably purified. However, those skilled in the art can, depending on the progress in technology, choose to work on crude samples. Any biological sample that may contain lymphocytes can be used; by way of nonlimiting examples of samples that can be used, mention may be made of blood, thymus, lymph node, spleen, PBMC, liver, skin, urine, etc., samples. 
     The implementation of the method above requires a high-performance Taq polymerase enzyme. It is in particular preferable to use an enzyme having the ability to amplify large fragments at high speed and that can “pass” over GC-rich regions. More preferably, in order to carry out multi-n-plex PCR reactions in the context of the present invention, those skilled in the art will choose a polymerase having the following characteristics: 
     (i) it is capable of amplifying fragments of several tens of kb; 
     (ii) its elongation rate is at least 1 kb/minute; 
     (iii) its robustness is such that it does not introduce more than one error per kb, on average. By way of nonlimiting examples of enzymes that can be used to implement this method, mention may be made of the HerculaseII polymerase from Stratagene and the Iproof polymerase from Biorad. 
     In the present text, the term “multi-n-plex PCR” refers to a polymerase chain reaction having n degrees of multiplexing, i.e. using, in the same reaction, n pairs of different primers, each allowing the amplification of at least two DNA fragments characteristic of at least two different chromosomal rearrangements. For example, in the TRA locus, a multi-2-plex PCR reaction can be carried out using a “sense” primer which specifically hybridizes upstream of and/or in a given V x  gene and two “antisense” primers which specifically hybridize downstream of and/or in two distinct J y  and J z  genes, allowing at least the amplification, in a single reaction, of fragments characteristic of the V x J y , V x J y+1 , V x J z  and V x J z+1  rearrangements. Of course, a multi-n-plex PCR reaction is possible only if the primers of the n pairs used are thermodynamically compatible. The thermodynamic compatibility of primers is a notion well known to those skilled in the art, who possess algorithms for verifying it. It implies in particular that the various primers have identical or close melting temperatures (Tm). In addition, the various primers should not hybridize to one another, nor form hairpins. In the rest of this text, the constraints linked to the compatibility of the primers for their simultaneous use in a multi-n-plex PCR will not be systematically recalled, given that they are part of the general knowledge of any molecular biologist. 
     In the present text, a “primer which specifically hybridizes downstream of and/or in a given J gene” may be referred to, by misuse of language, as “primer specific for the J gene”. Similarly, a “primer which specifically hybridizes upstream of and/or in a given V gene” may be referred to as “primer specific for the V gene”. As regards the V genes, it is important to note that they are, for most of the loci, grouped together in families, according to their degree of homology. In this case, a “primer specific for a given V gene” can in reality denote a primer which specifically recognizes all the members or some members of a family of V genes. Examples of primers specific for a family of V genes are given hereinafter. Moreover, when a pair of primers makes it possible to detect the rearrangements of all the members or of some members of the same family, these rearrangements may be referred to, by misuse of language, as “the rearrangement”, “the amplicon” or “the PCR product”. 
     The method above can in particular be applied to the analysis of the combinatorial diversity of the V-J rearrangements of at least one genetic locus chosen from the loci TRA, TRB, TRG, TRD, IgH, IgK, IgL, etc. 
     In one particular implementation of the method according to the invention, at least one primer of each pair of primers is labeled. When a primer is common to several pairs of primers used in the same multi-n-plex PCR, the other primer of each pair will preferably be labeled. Various labels, making it possible to distinguish the products of amplification by each of the pairs, can advantageously be used. Those skilled in the art possess a large variety of labels that can be used for labeling the primers, among which mention may be made of colorimetric labels, fluorescent labels, enzymatic labels, radioactive labels, biotin, streptavidin, etc. 
     According to one particular implementation of the method described above, step B) comprises a step of real-time measurement of the amplification of the DNA fragments; the interpretation of the amplification curves obtained is then carried out in the following way: 
     (i) if one or a few curves, the number thereof being less than half the curves, and in particular equal to 1, 2 or 3, exhibit(s) a shift compared with the other curves, such that the other curves exhibit a point of inflexion at least 2 cycles after the point of inflexion of the first curve, preferably at least 3 or cycles, or show(s) no amplification, the result indicates the presence of clonal or oligoclonal lympho-proliferation; 
     (ii) if, on the contrary, all the curves exhibit a point of inflexion at the same cycle, or within a maximum shift of 2 or 3 amplification cycles, the result makes it possible to discard the hypothesis of lymphoproliferation of a clone resulting from one of the rearrangements corresponding to the amplified fragments. 
     In this implementation, and according to the technology used to carry out the quantitative PCR (TaqMan®, measurement of the incorporation of a fluorescent intercalating agent such as SYBR-green®, etc.), the amplification measured is either the sum of the amplifications carried out with all the pairs of primers used in the same reaction (in the case of the use of SYBR-green®), or, on the contrary, the amplification by each of the pairs of primers, separately (in the case of the TaqMan® technology, using primers labeled differently for each of the pairs). Be that as it may, the inventors have observed that, when a given lymphocyte population is over-represented in a sample, the amplification of the fragment corresponding to the rearrangement that has occurred in these lymphocytes is efficient, whereas the amplification of the fragments corresponding to the other rearrangements results in a shifted curve, or even in a failure to amplify (flat curve). 
     When the amplification measurement is carried out with a fluorescent intercalating agent, the method described above may also comprise a step (optional) of confirmation of lymphoproliferation, by continuous measurement of the fluorescence in each tube during an increase in temperature between 40° C. and 95° C., the observation of a predominant peak being indicative of the presence of a predominant amplicon and therefore of a lymphoproliferation, whereas the observation of several peaks of similar sizes indicates, on the contrary, lymphocyte diversity. 
     This method also makes it possible to carry out a step of measurement of the molecular diversity of the rearrangements observed at the level of the genomic DNA, by measuring the molecular diversity of the amplicons. This optional step adds an additional degree of information since the “molecular diversity” results from the combination of the junctional diversity (CDR3), the combinatorial diversity (V-J) and the diversity derived from the somatic hypermutations. It is measured, according to the invention, in the following way: 
     (i) after dehybridization of the amplicons at 95° C., the temperature of the amplification products is rapidly brought back below 40° C., preferably to 30° C. or below; this decrease in temperature can be carried out in the thermocycler, or by placing the tube in ice for a few minutes; the drop in temperature should be carried out in a short period of time, preferably less than 2 minutes, even more preferably less than 30 seconds; 
     (ii) the fluorescence is measured regularly and preferably continually during the rehybridization; 
     (iii) a rapid rehybridization (of the order of a second) is indicative of the presence of a predominant amplicon, and therefore of clonal lymphoproliferation, whereas a slower rehybridization (of the order of several tens of seconds, or even minutes) is indicative of good molecular diversity (at least several tens of molecules, or even several thousand). 
     According to another preferred implementation of the method of the invention, step B) of detection of the amplification products comprises a step of separation of said products according to their size. Those skilled in the art possess several techniques for separating amplicons according to their size. By way of nonlimiting examples, mention may be made of agarose or polyacrylamide gel electrophoresis, or capillary electrophoresis, which has the advantage of being more readily automatable. The amplicons separated according to their size can be detected by any means known to those skilled in the art, in particular by virtue of labels bonded to the primers, or by using fluorescent intercalating agents such as ethidium bromide, SYBR-green®, etc. The resolution of the amplicons and the detection thereof make it possible to identify the various chromosomal rearrangements having given rise to amplification. The use of a semi-quantitative or quantitative amplification technique makes it possible, in addition, to determine the frequency, in the sample tested, of lymphocytes having undergone the V(D)J rearrangement corresponding to each of the amplicons observed. This implementation of the invention therefore makes it possible to finely evaluate the combinatorial diversity of a part of the immune repertoire, this part being all the greater the higher the number of rearrangements capable of giving rise to amplification, the latter parameter being dependent on the number of multiplex PCRs carried out, on their degree of multiplexing and on the choice of the primers. 
     Those skilled in the art may decide to implement the method of the invention by carrying out a first evaluation of the diversity of the lymphocyte repertoire by simple real-time measurement of the amplification of the DNA fragments, as mentioned above, and by subsequently carrying out a separation of the amplicons according to their size so as to obtain further information on the distribution of the various rearrangements in the lymphocyte population. In the case where lymphoproliferation is detected by quantitative multi-n-plex PCR, the second step, of detection, by separation of the amplicons according to their size, would make it possible in particular to identify the V(D)J rearrangement present in the proliferative clone or the few proliferative clones. It is important to note that this approach does not require additional PCRs to be carried out, since it is then sufficient to use the products of the PCRs already carried out, in order to separate the amplicons thereof according to their size. Alternatively, those skilled in the art can choose not to carry out the first step of searching for lymphoproliferation by real-time PCR, and to directly carry out the separation of the amplification products. Those skilled in the art will then directly obtain the name and the frequency (intensity) of the various V(D)J rearrangements having taken place in the lymphocyte population tested. 
     In this implementation of the invention, the pairs of primers used in combination in each multi-n-plex PCR reaction with n≧2 are preferably chosen in such a way that the majority of the amplicons obtained can be resolved according to their size. The term “resolved” is herein intended to mean that each of the amplicons can be observed individually, following size-separation thereof by means of an electrophoresis method or any other method. When amplicon sizes are too close, it is not always possible to discern them distinctly with separation conditions that are compatible with the conditions for “resolving” all the other amplicon sizes. The various amplicons obtained with a given pair of primers correspond to different rearrangements and are therefore of significantly different sizes. Care should therefore be taken to ensure that at least some of the products of amplification by a pair of primers have sizes different from the products of amplification by the other pair(s) of primers. Of course, the size differences for obtaining good band resolution depend on the technology used. By way of indication, size differences of 10% generally make it possible to obtain good resolution. Ideally, the primers are chosen so as to allow the resolution of all the amplicons. However, if some bands, corresponding to amplicons obtained with various pairs of primers in the same multi-n-plex PCR, are too close or overlap, other means can be used to identify and quantify the corresponding rearrangements. For example, distinct labels can be bonded to the corresponding primers (at least to one primer of each pair concerned). 
     In one particular implementation of the invention, at least one multi-n-plex PCR (with n≧2) is carried out using a combination of at least 3 primers constituting at least 2 pairs of primers comprising a common “sense” primer specific for a given V gene, each pair of primers also comprising an “antisense” primer specific for a given J gene. More particularly, this method may be advantageously implemented by carrying out several multi-2-plex PCRs with triplets of primers each constituted of a sense primer which specifically hybridizes upstream of and/or in a given V gene and of two antisense primers which specifically hybridize downstream of and/or in two distinct J genes. 
     An alternative way to combine the primers for carrying out the multi-n-plex PCRs according to the invention is to combine at least 3 primers constituting at least 2 pairs of primers comprising a common antisense primer specific for a given J gene, each pair of primers also comprising a sense primer specific for a given V gene. 
     The TRB locus has a particular configuration, since the J genes are arranged in two groups (or clusters) distant from one another, the first group (in the 5′→3′ direction) comprising the BJ1.1 to BJ1.6 genes, and the second group comprising the BJ2.1 to BJ2.7 genes. Taking advantage of this particular configuration, the inventors have determined parameters of choice for the primers for obtaining excellent resolution of the amplicons corresponding to the rearrangement of a given V gene with all or a part of the J genes. According to this particular implementation of the invention, at least one multi-n-plex PCR reaction with n≧2 is carried out in order to analyze certain rearrangements of the TRB locus, using a combination of at least 3 primers constituting at least 2 pairs of primers having the following characteristics: 
     (i) the two pairs of primers comprise a common sense primer which specifically hybridizes upstream of and/or in a given V gene and each comprise an antisense primer which specifically hybridizes downstream of and/or in a given J gene; 
     (ii) the two antisense primers specifically hybridize downstream of and/or in two genes J y  and J z  belonging to two distinct groups of J genes of the TRB locus; and 
     (iii) the distance between the region of hybridization of the antisense primer specific for the J y  gene and the start of said J y  gene is greater than the distance between the region of hybridization of the antisense primer specific for the J z  gene and the start of the first J gene of the group of genes of said J z  gene. 
     In the preceding text, the “distance between the region of hybridization of the antisense primer specific for the J y  gene and the beginning of said J y  gene” denotes the distance between the 3′ end of said region of hybridization (therefore corresponding, in the amplicon, to the 5′ end of the antisense primer specific for the J y  gene) and the first coding base of the J y  gene (located immediately after the RSS recombination sequence). 
     In one preferred implementation of this aspect of the invention, J y =J 1.6  and J z =J 2.7 . If V=V x , the bands characteristic of the rearrangements V x J2.7, V x J2.6, V x J 2.5 , V x J 2.4 , V x J 2.3 , V x J 2.2 , V x J 2.1 , V x J 1.6 , V x J 1.5 , V x J 1.4 , V x J 1.3 , V x J 1.2  and V x J 1.1  will therefore be seen, in increasing order of size. Where appropriate, if the polymerase used is particularly effective, a high-molecular-weight band corresponding to the V x J 1.n  arrangements amplified with the primer which hybridizes downstream of the J 2.7  gene will also be observed. Alternatively, the method may be implemented with J y =J 2.7  and J z =J 1.6 , which will result in the bands characteristic of the rearrangements V x J 1.6 , V x J 1.5 , V x J 1.4 , V x J 1.3 , V x J 1.2 , V x J 1.1 , V x J 2.7 , V x J 2.6 , V x J 2.5 , V x J 2.4 , V x J 2.3 , V x J 2.2  and V x J 2.1 , in increasing order, being observed. 
     According to one preferred implementation of the method described above for analyzing certain rearrangements of the TRB locus, at least one multi-n-plex PCR reaction with n≧2 is carried out using a combination of at least 3 primers comprising the primers hTRBJ1.6 and hTRJB2.7 defined in the following way:
         hTRBJ1.6 (CTTGGTGCATGGCTATGTAATCCTG, SEQ ID No 1) is an antisense oligonucleotide of 25 nucleotides which hybridizes between nucleotides 2341 and 2365 of the J1.6 gene of the TCRB locus; and   hTRBJ2.7 (CTCGCCCTCTGCTCAGCTTTCC, SEQ ID No 2) is an antisense oligonucleotide of 22 nucleotides which hybridizes between nucleotides 214 and 235 of the J2.7 gene of the TCRB locus.       

     A method for determining the position of the various primers described in the present text, relative to various genes of the TCR or IgH loci, is explained in example 1 hereinafter. The genomic sequences disclosed in the “Ensembl Genome Browser” database can be used to identify primers that can be used in the context of the present invention. 
     The inventors have identified, in the TRB locus, 24 families of functional V genes. They have also shown that, by carrying out at least 23 multi-2-plex PCRs, it is possible to analyze at least 75% of the V(D)J rearrangements of the TRB locus, involving more than 85% of the V families. The invention therefore relates more particularly to a method for analyzing at least 75%, preferably at least 80% of the V(D)J rearrangements of the TRB locus by carrying out 23 or 24 multi-n-plex PCRs with n≧2 using combinations of at least 3 primers, each combination of primers comprising the hTRBJ1.6 and hTRBJ2.7 primers, defined above, and at least one hTRBV primer chosen from the primers defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 2 
               
               
                   
               
               
                   
                   
                   
                 Distance between 
                   
                   
               
               
                   
                   
                   
                 the 5′ end 
                   
                   
               
               
                   
                   
                   
                 of the primer 
                   
                   
               
               
                   
                   
                   
                 and the end of 
                   
                   
               
               
                   
                   
                 Size 
                 the V gene 
                   
                 SEQ 
               
               
                 Name of gene 
                 Name of primer 
                 (nt) 
                 (bp) 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 TRBV2 
                 hTRBV2up2 
                 26 
                 255 
                 CACACAGATGGGAC 
                  3 
               
               
                   
                   
                   
                   
                 AGGAAGTGATCT 
                   
               
               
                   
               
               
                 TRBV4 
                 hTRBV4up EX 
                 23 
                 100 
                 GCTTCTCACCTGAA 
                  4 
               
               
                   
                   
                   
                   
                 TGCCCCAAC 
                   
               
               
                   
               
               
                 TRBV5.1, 3, 4, 
                 hTRBV5up_ex1/2 
                 25 
                 256 
                 CTGATCAAAACGAG 
                  5 
               
               
                 5, 6, 8 
                   
                   
                   
                 AGGACAGCAAG 
                   
               
               
                   
               
               
                 TRBV5.7 
                 hTRBV5up_ex2/2 
                 25 
                 256 
                 CTGATCAAAACGAG 
                  6 
               
               
                   
                   
                   
                   
                 AGGACAGCACG 
                   
               
               
                   
               
               
                 TRBV6.4 
                 hTRBV6up_ex2/2 
                 23 
                 279 
                 GATCACCCAGGCAC 
                  7 
               
               
                   
                   
                   
                   
                 CAACATCTC 
                   
               
               
                   
               
               
                 TRBV7.2 
                 hTRBV7up_ex2/3 
                 25 
                 301 
                 CAGATCACACAGGA 
                  8 
               
               
                   
                   
                   
                   
                 GCTGGAGTCTC 
                   
               
               
                   
               
               
                 TRBV7.9 
                 hTRBV7up_ex3/3 
                 27 
                 303 
                 CACAGATCACGCAG 
                  9 
               
               
                   
                   
                   
                   
                 ATACTGGAGTCTC 
                   
               
               
                   
               
               
                 TRBV9 
                 hTRBV9up_ex 
                 23 
                  92 
                 CGCACAACAGTTCC 
                 10 
               
               
                   
                   
                   
                   
                 CTGACTTGC 
                   
               
               
                   
               
               
                 TRBV11 
                 hTRBV11up_ex 
                 27 
                 120 
                 TTCACAGTTGCCTA 
                 11 
               
               
                   
                   
                   
                   
                 AGGATCGATTTTC 
                   
               
               
                   
               
               
                 TRBV12.1 
                 hTRBV12.1up1 
                 27 
                 196 
                 TTCTCTGGTACAGA 
                 12 
               
               
                   
                   
                   
                   
                 CAGACCTTTGTGC 
                   
               
               
                   
               
               
                 TRBV12.2 
                 hTRBV12.2up1 
                 27 
                 196 
                 TTTTCTGGTACAGA 
                 13 
               
               
                   
                   
                   
                   
                 GATACCTTCGTGC 
                   
               
               
                   
               
               
                 TRBV13 
                 hTRBV13up1 
                 25 
                 356 
                 GTTGCTGAAGTGTC 
                 14 
               
               
                   
                   
                   
                   
                 AAACTCTCCCG 
                   
               
               
                   
               
               
                 TRBV14 
                 hTRBV14up_ex 
                 24 
                 271 
                 TCCCCAGCCACAGC 
                 15 
               
               
                   
                   
                   
                   
                 GTAATAGAGA 
                   
               
               
                   
               
               
                 TRBV15 
                 hTRBV15up_ex 
                 24 
                 163 
                 CCCCAAAGCTGCTG 
                 16 
               
               
                   
                   
                   
                   
                 TTCCACTACT 
                   
               
               
                   
               
               
                 TRBV16 
                 hTRBV16up1 
                 22 
                 295 
                 CTCCTGGTGAAGAA 
                 17 
               
               
                   
                   
                   
                   
                 GTCGCCCA 
                   
               
               
                   
               
               
                 TRBV18 
                 hTRBV18up1 
                 22 
                  46 
                 TAGTGCGAGGAGAT 
                 18 
               
               
                   
                   
                   
                   
                 TCGGCAGC 
                   
               
               
                   
               
               
                 TRBV19 
                 hTRBV19up2 
                 24 
                 217 
                 CTGGGAGCAAGTGA 
                 19 
               
               
                   
                   
                   
                   
                 GTCCTGGGT 
                   
               
               
                   
               
               
                 TRBV20 
                 hTRBV20-1up_ex 
                 24 
                  91 
                 TCATCAACCATGCA 
                 20 
               
               
                   
                   
                   
                   
                 AGCCTGACCT 
                   
               
               
                   
               
               
                 TRBV24 
                 hTRBV24up_ex 
                 24 
                  96 
                 AGTGTCTCTCGACA 
                 21 
               
               
                   
                   
                   
                   
                 GGCACAGGCT 
                   
               
               
                   
               
               
                 TRBV25 
                 hTRBV25up_int 
                 23 
                 273 
                 CCTCTTTGTTGGGT 
                 22 
               
               
                   
                   
                   
                   
                 TTGTGCCTG 
                   
               
               
                   
               
               
                 TRBV27 
                 hTRBV27up2 
                 22 
                 312 
                 GTCCCCTTCCTTTA 
                 23 
               
               
                   
                   
                   
                   
                 CAGGCCCC 
                   
               
               
                   
               
               
                 TRBV29 
                 hTRBV29up_G 
                 21 
                  91 
                 CCATCAGCCGCCCA 
                 24 
               
               
                   
                   
                   
                   
                 AACCTAA 
                   
               
               
                   
               
               
                 TRBV30 
                 hTRBV30up1 
                 26 
                 148 
                 TGCTCTTCTACTCC 
                 25 
               
               
                   
                   
                   
                   
                 GTTGGTATTGGC 
                   
               
               
                   
               
            
           
         
       
     
     This implementation of the invention enables an analysis of at least 80% of the V(D)J rearrangements of the TRB locus, i.e., for more than 85% of the families of functional V genes, determination of the frequency of use of the genes of each functional V family with each functional J family of this locus (without information on the nature of the D gene used in these rearrangements, nor on the use of each member of a given V family, nor on the junctional diversity of the rearrangements, etc.). Coupling with a real-time measurement of the amplification by multi-n-plex PCR also makes it possible to estimate the molecular diversity. 
     According to another particular implementation of the method of the invention, this method enables the in vitro detection of incomplete D-J rearrangements in a genetic locus chosen from the TRB and IgH loci. The detection of the incomplete rearrangements is important since, even if they are nonfunctional, they constitute, in certain cases, the only signature of a lympho-proliferative population. 
     This method can in particular be suitable for analyzing incomplete DJ rearrangements of the human TRB locus, by carrying out at least one multi-n-plex PCR reaction with n≧2 with a combination of at least 3 primers constituting at least 2 pairs of primers having the following characteristics: 
     (i) the two pairs of primers comprise a common sense primer which specifically hybridizes upstream of and/or in a given D gene and each comprise an antisense primer which specifically hybridizes downstream of and/or in a given J gene; 
     (ii) the two antisense primers which specifically hybridize downstream of and/or in two genes J y  and J z  belonging to two distinct groups of J genes of the TRB locus; and 
     (iii) the distance between the region of hybridization of the antisense primer specific for the J y  gene and the start of said J y  gene is greater than the distance between the region of hybridization of the antisense primer specific for the J z  gene and the start of the first J gene of the group of genes of said J z  gene. 
     In particular, the hTRBJ1.6 and hTRBJ2.7 primers defined above can be combined with a sense primer which specifically hybridizes upstream of and/or in a given D gene, in order to carryout a multi-n-plex PCR reaction with n≧2. 
     Owing to the configuration of the TRB locus, it is possible to analyze all the incomplete DJ rearrangements of this locus with only 2 multi-2-plex PCRs. 
     Thus, it is possible to analyze all the incomplete rearrangements of the human TRB locus by carrying out (i) a multi-2-plex PCR using a triplet of primers constituted of the hTRBJ1.6 and hTRBJ2.7 primers and of an hTRBD1 primer, and (ii) a simple multiplex PCR using the pair of primers constituted of the hTRBJ2.7 primers and of an hTRBD2 primer, by choosing, for example, the hTRBD1 and hTRBD2 primers from the primers defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 3 
               
               
                   
               
               
                   
                   
                   
                 Distance between 
                   
                   
               
               
                   
                   
                   
                 the 5′ end 
                   
                   
               
               
                   
                   
                   
                 of the primer 
                   
                   
               
               
                   
                 Oligo- 
                   
                 and the end of 
                   
                   
               
               
                 Name 
                 nucleotide 
                 Size 
                 the D gene 
                   
                 SEQ 
               
               
                 of gene 
                 name 
                 (nt) 
                 (bp) 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 TRBD1 
                 hTRBD1up1 
                 25 
                 325 
                 TTCTCTATAAGGACATGCCCC 
                 26 
               
               
                   
                   
                   
                   
                 AACG 
                   
               
               
                   
               
               
                 TRBD1 
                 hTRBD1up2 
                 23 
                 289 
                 TTGGAGAGGGGTGGGTACTGG 
                 27 
               
               
                   
                   
                   
                   
                 AG 
                   
               
               
                   
               
               
                 TRBD2 
                 hTRBD2up1 
                 26 
                 322 
                 CTCCCACCCACTTCACTATAA 
                 28 
               
               
                   
                   
                   
                   
                 ATGCC 
                   
               
               
                   
               
               
                 TRBD2 
                 hTRBD2up2 
                 21 
                 290 
                 GAGCAGGTGGGCACAGTGAGC 
                 29 
               
               
                   
               
            
           
         
       
     
     When the analysis of the incomplete rearrangements of the TRB locus is coupled with the analysis of other rearrangements, the multiplex PCRs described above, in particular the simple multiplex PCR, can be combined with other amplification reactions, carried out in the same tube (thus increasing the degree of multiplexing and reducing the number of reactions necessary for analyzing a given number of rearrangements). 
     According to one preferred implementation of the invention, the method combines the analysis of the V(D)J rearrangements of the TRB locus and that of the incomplete rearrangements of this locus, by implementation of the suitable variants described above. The primers described above for this analysis are suitable for the analysis of the rearrangements of this locus in humans, but this method can be transposed, without any difficulty, to animals, for example to mice. Primers that can be used in mice are described, by way of example, in the experimental section which follows. 
     According to another aspect of the invention, the method makes it possible to analyze the rearrangements of 95% of the J genes of the human TRA locus with a given V gene of the same locus, by carrying out, in step A), between 3 and 6 multi-n-plex PCRs with n≧2, with combinations of primers each constituted of a primer which hybridizes upstream of and/or in said V gene and of one or two pair(s) of antisense primers chosen from the pairs (hTRAJ56, hTRAJ41), (hTRAJ37, hTRAJ33), (hTRAJ48, hTRAJ29), (hTRAJ24, hTRAJ18), (hTRAJ53, hTRAJ11) and (hTRAJ7, hTRAJ3), said primers being defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 4 
               
               
                   
               
               
                   
                   
                   
                 Distance 
                   
                   
               
               
                   
                   
                   
                 with the 
                   
                   
               
               
                   
                   
                   
                 start of 
                   
                   
               
               
                   
                 Oligo- 
                   
                 the J 
                   
                   
               
               
                 Name 
                 nucleotide 
                 Size 
                 gene in 
                   
                 SEQ 
               
               
                 of gene 
                 name 
                 (nt) 
                 bp 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 hTRAJ56 
                 hTRAJ56do 
                 24 
                 883 
                 TCCCCCAAGTATTGCATTTGGATT 
                 30 
               
               
                   
               
               
                 hTRAJ41 
                 jTRAJ41do 
                 25 
                 443 
                 AACTCAACAGGGTCCTTGCCACTTA 
                 31 
               
               
                   
               
               
                 hTRAJ37 
                 hTRAJ37do 
                 28 
                 351 
                 CCACCCACATTTGATGTTTTTATTTCTT 
                 32 
               
               
                   
               
               
                 hTRAJ33 
                 hTRAJ33do 
                 24 
                  98 
                 TAGTGTCTCCTCTCCCGTGCAGTC 
                 33 
               
               
                   
               
               
                 hTRAJ48 
                 hTRAJ48do 
                 28 
                  43 
                 GTTCCAGTCCCAAAGGTTAATTTCTCAT 
                 34 
               
               
                   
               
               
                 hTRAJ29 
                 hTRAJ29do 
                 24 
                 300 
                 AGAACAAGCTGGAGGCAACTAGGC 
                 35 
               
               
                   
               
               
                 hTRAJ24 
                 hTRAJ24do 
                 28 
                 227 
                 AACACCAGTCTGATCTCTCATTTTTGCT 
                 36 
               
               
                   
               
               
                 hTRAJ18 
                 hTRAJ18do 
                 29 
                 147 
                 CAAGACTAAAGGAGTTAATTCATCTCCCC 
                 37 
               
               
                   
               
               
                 hTRAJ53 
                 hTRAJ53do 
                 24 
                 200 
                 AATCCCTCTGATGGGCACCATATC 
                 38 
               
               
                   
               
               
                 hTRAJ11 
                 hTRAJ11do 
                 20 
                  88 
                 ACATGGGTGGGATGGGGTCA 
                 39 
               
               
                   
               
               
                 hTRAJ7 
                 hTRAJ7do 
                 20 
                 478 
                 TGGGAGTAAAGGGCTGGGGC 
                 40 
               
               
                   
               
               
                 hTRAJ3 
                 hTRAJ3do 
                 25 
                 329 
                 AACCTCAATTCCAGGCAGCAGTATC 
                 41 
               
               
                   
               
            
           
         
       
     
     This analysis can in particular be carried out using 6 multi-2-plex PCRs. Alternatively, it can be carried out using 3 multi-4-plex PCRs performed with combinations of primers each comprising a sense primer specific for a V gene and a quadruplet of primers chosen from the following quadruplets: (hTRAJ56, hTRAJ41, hTRAJ37, hTRAJ33), (hTRAJ48, hTRAJ29, hTRAJ24, hTRAJ18) and (hTRAJ53, hTRAJ11, hTRAJ7, hTRAJ3). Of course, the intermediate situations (4 multi-2-plex PCRs and 1 multi-4-plex PCR; 2 multi-2-plex PCRs and 2 multi-4-plex PCRs) are also envisioned. 
     In order to have more comprehensive information on the rearrangements of the TRA locus, it is proposed to carry out the method described above with at least three, but preferably 4, 5, 6 or more, primers which hybridize upstream of and/or in the distinct V genes, each located in a distinct region of the locus. It is important for the TRAV genes targeted by these primers to be well distributed in the locus, in order for the combinatorial diversity observed to be actually representative of all the rearrangements of this locus. Primers that can be used for this are defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 5 
               
               
                   
               
               
                   
                   
                   
                 Distance 
                   
                   
               
               
                   
                   
                   
                 with the 
                   
                   
               
               
                   
                   
                   
                 end of 
                   
                   
               
               
                 Name 
                 Name of 
                 Size 
                 the V gene 
                   
                 SEQ 
               
               
                 of gene 
                 oligonucleotide 
                 (bp) 
                 (bp) 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 TRAV1 
                 hTRAV1up_ex 
                 26 
                 104 
                 GGTCGTTTTTCTTCATTCCTTAGTCG 
                 42 
               
               
                   
               
               
                 TRAV3 
                 hTRAV3 
                 22 
                 377 
                 TCCCCTTCCCATTTTCCACTCG 
                 43 
               
               
                   
               
               
                 TRAV4 
                 hTRAV4up_ex_testAn1 
                 23 
                  96 
                 CCCTGTTTATCCCTGCCGACAGA 
                 44 
               
               
                   
               
               
                 TRAV10 
                 hTRAV10upn3 
                 24 
                  85 
                 CTGGATGCAGACACAAAGCAAAGC 
                 45 
               
               
                   
               
               
                 TRAV12.2, 3 
                 hTRAV12.2, 3up1 
                 27 
                 114 
                 AATGAAGATGGAAGGTTTACAGCACAG 
                 46 
               
               
                   
               
               
                 TRAV12.1 
                 hTRAV12.1up1 
                 28 
                 112 
                 ACAAAGAAGATGGAAGGTTTACAGCACA 
                 47 
               
               
                   
               
               
                 TRAV14 
                 hTRAV14upn2 
                 22 
                  69 
                 CGCCAACCTTGTCATCTCCGCT 
                 48 
               
               
                   
               
               
                 TRAV16 
                 hTRAV16upn5 
                 27 
                 118 
                 CTAGAGAGAGCATCAAAGGCTTCACTG 
                 49 
               
               
                   
               
               
                 TRAV17 
                 hTRAV17upn2 
                 22 
                  40 
                 CGGGCAGCAGACACTGCTTCTT 
                 50 
               
               
                   
               
               
                 TRAV19 
                 hTRAV19up 
                 24 
                 144 
                 TCGTCGGAACTCTTTTGATGAGCA 
                 51 
               
               
                   
               
               
                 TRAV21 
                 hTRAV21up 
                 24 
                  91 
                 TGCCTCGCTGGATAAATCATCAGG 
                 52 
               
               
                   
               
               
                 TRAV22 
                 hTRAV22up 
                 21 
                  42 
                 CCCAGACCACAGACTCAGGCG 
                 53 
               
               
                   
               
               
                 TRAV23 
                 hTRAV23upn2 
                 28 
                 130 
                 CGTCCAGATGTGAGTGAAAAGAAAGAAG 
                 54 
               
               
                   
               
               
                 TRAV25 
                 hTRAV25upn3 
                 27 
                 154 
                 TGGACATCCCGTTTTTTTGATACAGTT 
                 55 
               
               
                   
               
               
                 TRAV27 
                 hTRAV27up 
                 27 
                 138 
                 TGGTGACAGTAGTTACGGGTGGAGAAG 
                 56 
               
               
                   
               
               
                 TRAV29 
                 hTRAV29up 
                 24 
                 267 
                 AGCAAAATTCACCATCCCTGAGCG 
                 57 
               
               
                   
               
               
                 TRAV30 
                 hTRAV30upn2 
                 24 
                 139 
                 TGAAGGGTGGAGAACAGAAGGGTC 
                 58 
               
               
                   
               
               
                 TRAV35 
                 hTRAV35_int_up 
                 27 
                 377 
                 GGCTGGGAAGTTTGGTGATATAGTGTC 
                 59 
               
               
                   
               
               
                 TRAV36 
                 hTRAV36_int_upn2 
                 27 
                 304 
                 ACATTTTTCTACACAGGGGTGAGCAGT 
                 60 
               
               
                   
               
               
                 TRAV41 
                 hTRAV41_int_up 
                 28 
                 368 
                 GCCCTCCTGAAAATGTGTAAAGAAATGT 
                 61 
               
               
                   
               
            
           
         
       
     
     The implementation of the method by carrying out, for each of the 20 TRAV primers described in this table, 6 multi-2-plex PCRs (or 3 multi-4-plex PCRs, etc.) with the combinations described above in order to observe the rearrangements of 95% of the TRAJ genes with a V gene, makes it possible to observe between 50% and 75% of all the VJ rearrangements of the TRA locus. 
     Of course, those skilled in the art can transpose this method to the analysis of the TRA locus of an animal, for example to the murine TRA locus. 
     According to another aspect, the invention relates to a method for analyzing the rearrangements of all the J genes of the human TRG locus with at least 2 given genes V x  and V y  of the same locus, by carrying out, in step A), at least one multi-2-plex PCR with a triplet of primers constituted of 2 sense primers which hybridize upstream of and/or in said V x  and V y  genes and of the antisense primer hTRGJdo2 (ACATATGAGCCCTTTATGGAAGTCCG, SEQ ID No. 62) of 26 nucleotides which hybridizes in the J2 gene of the human TRG locus. 
     By way of examples of primers which hybridize upstream of and/or in a V gene of the human TRG locus, that can be used for implementing this aspect of the invention, mention may be made of the primers defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 6 
               
               
                   
               
               
                   
                   
                   
                 Distance 
                   
                   
               
               
                   
                   
                   
                 with the 
                   
                   
               
               
                   
                 Oligo- 
                   
                 end of the 
                   
                   
               
               
                 Name 
                 nucleotide 
                 Size 
                 V gene in 
                   
                 SEQ 
               
               
                 of gene 
                 name 
                 (nt) 
                 bp 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 TRGV1.2 
                 hTRGV1.2up1 
                 30 
                  99 
                 TATTATACTTACGCAAGCACAAGGAACAAC 
                 63 
               
               
                   
               
               
                 TRGV1.4 
                 hTRGV1.4up1 
                 28 
                 158 
                 TGTACTATGACTCCTACACCTCCAGCGT 
                 64 
               
               
                   
               
               
                 TRGV1.5 
                 hTRGV1.5up1 
                 23 
                 287 
                 AAGGGGGAACGAAGTCAGTCACG 
                 65 
               
               
                   
               
               
                 TRGV1.8 
                 hTRGV1.8up1 
                 26 
                 129 
                 GTGTTGGAATCAGGAATCAGTCGAGA 
                 66 
               
               
                   
               
            
           
         
       
     
     This analysis can in particular be carried out by performing only simple multiplex PCRs, or multi-n-plex PCRs with n≧2, with, in the same reaction, a pair of primers specific for the TRG locus and a pair of primers specific for another locus. 
     The diversity of the rearrangements involved in the TRD locus can also be studied by means of a method according to the invention, by carrying out, in step A), a multi-2-plex PCR with a triplet of primers constituted of a primer which hybridizes upstream of and/or in a V gene of this locus and of the antisense primers hTRDJ1do5 and hTRDJ3do2, defined as follows:
         hTRDJ1do5 (TGCCTCCTTAGATGGAGGATGCC, SEQ ID No. 67) is an antisense oligonucleotide of 23 nucleotides which hybridizes between nucleotides 90 and 112 of the J1 gene of the TRD locus; and   hTRDJ3do2 (GCAAGGAGGCACGCATACTAGTTAGC, SEQ ID No 68) is an antisense oligonucleotide of 26 nucleotides which hybridizes between nucleotides 448 and 473 of the J3 gene of the TRD locus.       

     With this combination of primers, it is possible to analyze, using a single multi-2-plex PCR, the rearrangements of all the J genes of the human TRD locus with a given V gene. The complete analysis of all the VJ rearrangements of the TRD locus can therefore be obtained by carrying out a multi-n-plex PCR with n≧2, per TRDV family. By way of examples of primers specific for TRDV genes that can be used with the antisense primers hTRDJ1do5 and hTRDJ3do2 for implementing this aspect of the invention, mention may be made of the primers defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 7 
               
               
                   
               
               
                   
                   
                   
                 Distance between 
                   
                   
               
               
                   
                   
                   
                 the 5′ end 
                   
                   
               
               
                   
                   
                   
                 of the primer 
                   
                   
               
               
                   
                   
                   
                 and the end of 
                   
                   
               
               
                   
                   
                 Size 
                 the V gene 
                   
                 SEQ 
               
               
                 Name of gene 
                 Name of primer 
                 (nt) 
                 (bp) 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 TRAV12.1 
                 hTRAV12.1up1 
                 28 
                 112 
                 ACAAAGAAGATGGAAGG 
                 69 
               
               
                   
                   
                   
                   
                 TTTACAGCACA 
                   
               
               
                   
               
               
                 TRAV14 
                 hTRAV14upn2 
                 22 
                  69 
                 CGCCAACCTTGTCATCT 
                 70 
               
               
                 (TRDV4) 
                   
                   
                   
                 CCGCT 
                   
               
               
                   
               
               
                 TRAV16 
                 hTRAV16upn5 
                 27 
                 118 
                 CTAGAGAGAGCATCAAA 
                 71 
               
               
                   
                   
                   
                   
                 GGCTTCACTG 
                   
               
               
                   
               
               
                 TRAV17 
                 hTRAV17upn2 
                 22 
                  40 
                 CGGGCAGCAGACACTGC 
                 72 
               
               
                   
                   
                   
                   
                 TTCTT 
                   
               
               
                   
               
               
                 TRAV21 
                 hTRAV21up 
                 24 
                  91 
                 TGCCTCGCTGGATAAAT 
                 73 
               
               
                   
                   
                   
                   
                 CATCAGG 
                   
               
               
                   
               
               
                 TRAV22 
                 hTRAV22up2 
                 21 
                 232 
                 CAGGAGGGAGCCAATTC 
                 74 
               
               
                   
                   
                   
                   
                 CACG 
                   
               
               
                   
               
               
                 TRAV23 
                 hTRAV23upn2 
                 28 
                 130 
                 CGTCCAGATGTGAGTGA 
                 75 
               
               
                 (TRDV6) 
                   
                   
                   
                 AAAGAAAGAAG 
                   
               
               
                   
               
               
                 TRAV25 
                 hTRAV25upn3 
                 27 
                 154 
                 TGGACATCCCGTTTTTT 
                 76 
               
               
                   
                   
                   
                   
                 TGATACAGTT 
                   
               
               
                   
               
               
                 TRAV29 
                 hTRAV29up 
                 24 
                 267 
                 AGCAAAATTCACCATCC 
                 77 
               
               
                 (TRDV5) 
                   
                   
                   
                 CTGAGCG 
                   
               
               
                   
               
               
                 TRAV30 
                 hTRAV30upn2 
                 24 
                 139 
                 TGAAGGGTGGAGAACAG 
                 78 
               
               
                   
                   
                   
                   
                 AAGGGTC 
                   
               
               
                   
               
               
                 TRAV35 
                 hTRAV35_intup 
                 27 
                 377 
                 GGCTGGGAAGTTTGGTG 
                 79 
               
               
                   
                   
                   
                   
                 ATATAGTGTC 
                   
               
               
                   
               
               
                 TRAV36 
                 hTRAV36up1 
                 26 
                 280 
                 AGTGAAGACAAGGTGGT 
                 80 
               
               
                 (TRDV7) 
                   
                   
                   
                 ACAAAGCCC 
                   
               
               
                   
               
               
                 TRAV39 
                 hTRAV39up1 
                 26 
                 352 
                 GGGAGGAACAGGATTAT 
                 81 
               
               
                   
                   
                   
                   
                 TGGGGTAAC 
                   
               
               
                   
               
               
                 TRAV41 
                 hTRAV41_intup 
                 28 
                 368 
                 GCCCTCCTGAAAATGTG 
                 82 
               
               
                   
                   
                   
                   
                 TAAAGAAATGT 
                   
               
               
                   
               
               
                 TRDV1 
                 hTRDV1up1 
                 25 
                 259 
                 CAGTATCCATGCCAGTG 
                 83 
               
               
                   
                   
                   
                   
                 AGGAAAGC 
                   
               
               
                   
               
               
                 TRDV3 
                 hTRDV3up1 
                 24 
                 287 
                 GACAAAGTAACCCAGAG 
                 84 
               
               
                   
                   
                   
                   
                 TTCCCCG 
                   
               
               
                   
               
            
           
         
       
     
     According to another variant, the invention also makes it possible to analyze the rearrangements of all the J genes of the human IgH locus with at least 2 given genes V x  and V y  of the same locus, by carrying out at least one multi-n-plex PCR with n≧2 (and in particular with n=2), with a combination of primers comprising 2 sense primers which hybridize upstream of and/or in said V x  and V y  genes and one antisense primer which hybridizes downstream of and/or in the IgHJ6 gene, for example the primer hIgHJ6do2 (GATCTTGCAGTCCTACAGACACCGC, SEQ ID No 85), which hybridizes between base 368 and base 392 starting from the beginning of the IgHJ6 gene. 
     By way of primers which hybridize upstream of and/or in a V gene of the human IgH locus, that can be used according to this aspect of the invention, mention may be made of the primers defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 8 
               
               
                   
               
               
                   
                   
                   
                 Distance 
                   
                   
               
               
                   
                   
                   
                 with the 
                   
                   
               
               
                   
                 Oligo- 
                   
                 end of the 
                   
                   
               
               
                 Name 
                 nucleotide 
                 Size 
                 V gene in 
                   
                 SEQ 
               
               
                 of gene 
                 name 
                 (nt) 
                 bp 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 IgHV1.2, 8, 18, 
                 hIgHV1Aup1 
                 25 
                 172 
                 GACAAGGGCTTGAGTGGATGGG 
                 86 
               
               
                 46, 69 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 IgHV2 
                 hIgHV2up1 
                 22 
                  44 
                 CATGGACCCTGTGGACACAGCC 
                 87 
               
               
                   
               
               
                 IgHV3.7, 13, 15, 
                 hIgHV3Aup1 
                 24 
                 315 for 
                 TGTTTGCAGGTGTCCAGTGTGA 
                 88 
               
               
                 20, 21, 23, 48, 
                   
                   
                 V3.7 
                 GG 
                   
               
               
                 53, 64, 66, 72, 
                   
                   
                   
                   
                   
               
               
                 73, 74 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 IgHV4 
                 hIgHV4up1 
                 25 
                  69 
                 GAACCAGTTCTCCCTGAAGCTG 
                 89 
               
               
                   
                   
                   
                   
                 AGC 
                   
               
               
                   
               
               
                 IgHV5 
                 hIgHV5up1 
                 21 
                  55 
                 TGCAGTGGAGCAGCCTGAAGG 
                 90 
               
               
                   
               
               
                 IgHV6 
                 hIgHV6up1 
                 23 
                 371 
                 AGCAGCATTCACAGACTGAGGG 
                 91 
               
               
                   
                   
                   
                   
                 G 
                   
               
               
                   
               
            
           
         
       
     
     According to one particular implementation of this method, the primers specific for the V x  and V y  genes of the IgH locus are chosen such that the sum of the distance between the 5′ end of the region of hybridization of the primer specific for V x  and the end of said V x  gene, and of the distance between the 5′ end of the coding sequence of the IgHJ1 gene and the 3′ end of the region of hybridization of the hIgHJ antisense primer is greater than the sum of the distance between the 5′ end of the region of hybridization of the primer specific for V y  and the end of said V y  gene, and of the distance between the 5′ end of the coding sequence of the IgHJ6 gene and the 3′ end of the region of hybridization of the hIgHJ6 antisense primer. This enables the amplicon corresponding to V x J6 to be larger than that corresponding to V y J1, so as to have resolution of the amplicons in the order V y J6, V y J5, . . . , V y J1, V x J6, . . . , V x J1. 
     However, given the size of the cluster of IgHJ genes, the primers specific for the V x  and V y  genes of the IgH locus will preferably be chosen so as to obtain an “embedded” arrangement of the amplicons, i.e. such that at least one amplicon obtained with a first pair of primers is bordered by 2 amplicons obtained with a second pair of primers. 
     The method of the invention also makes it possible to analyze the incomplete rearrangements of the human IgH locus, by carrying out at least one multi-n-plex PCR reaction with n≧2, with a combination of at least 3 primers constituting at least 2 pairs of primers comprising a common antisense primer which specifically hybridizes downstream of and/or in a given J gene, such as, for example, the hIgHJ6do2 primer described above, each pair of primers also comprising a sense primer which specifically hybridizes upstream of and/or in a given D gene. 
     By way of examples of primers which hybridize upstream of and/or in a D gene of the human IgH locus, that can be used according to this aspect of the invention, mention may be made of the primers defined in the table below: 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 9 
               
               
                   
               
               
                   
                   
                   
                 Distance between 
                   
                   
               
               
                   
                   
                   
                 the 5′ end 
                   
                   
               
               
                   
                   
                   
                 of the primer 
                   
                   
               
               
                   
                 Oligo- 
                   
                 and the end of 
                   
                   
               
               
                 Name 
                 nucleotide 
                 Size 
                 the D gene 
                   
                 SEQ 
               
               
                 of gene 
                 name 
                 (bp) 
                 (bp) 
                 Sequence 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 hIgDH1 
                 hIgHD1up1 
                 23 
                  44 
                 GATTCTGAACAGCCCCGAGTCAC 
                 92 
               
               
                   
               
               
                 hIgHD2 
                 hIgHD2up1 
                 22 
                  67 
                 GGACAGGAGGATTTTGTGGGGG 
                 93 
               
               
                   
               
               
                 hIgHD3 
                 hIgHD3up1 
                 20 
                 102 
                 AGGTCAGCCCTGGACATCCC 
                 94 
               
               
                   
               
               
                 hIgHD4 
                 hIgHD4up1 
                 19 
                 132 
                 ATCCCCAGGACGCAGCACC 
                 95 
               
               
                   
               
               
                 hIgHD5 
                 hIgHD5up2 
                 20 
                  85 
                 AGCTCCTCCTGACAGCCCCG 
                 96 
               
               
                   
               
               
                 hIgHD6 
                 hIgHD6up1 
                 21 
                 160 
                 ACACCAGACAGAGGGGCAGGC 
                 97 
               
               
                   
               
               
                 hIgHD7 
                 hIgHD7up2 
                 20 
                  90 
                 AGACCGCAGCCACATCAGCC 
                 98 
               
               
                   
               
            
           
         
       
     
     This analysis can in particular be carried out by performing only simple multiplex PCRs, or multi-n-plex PCRs with n≧2, with, in the same reaction, a pair of primers specific for the IgH locus and a pair of primers specific for another locus. 
     According to one preferred implementation of the invention, the method combines the analysis of the V(D)J rearrangements of the IgH locus and that of the incomplete rearrangements of this locus, by implementing the suitable variants described above. The primers described above for this analysis are suitable for the analysis of the rearrangements of this locus in humans, but this method can be transposed, without any difficulty, to animals, for example to mice. 
     According to another implementation of the invention, the method is suitable for analyzing the combinatorial diversity of the V(D)J rearrangements of at least two genetic loci chosen from the TRA, TRB, TRG, TRD, IgH, IgK and IgL loci, by combining the suitable variants described above. The analysis of the various loci can be carried out simultaneously or sequentially, by performing, as appropriate, multi-n-plex PCRs with, in the same reaction, at least one pair specific for one locus and another pair specific for another locus. 
     In particular, the combined analysis of the combinatorial diversity of the V(D)J rearrangements of the TRB locus and of the combinatorial diversity of the VJ rearrangements of the TRG locus or of the TRD locus makes it possible to have a representative view of the repertoire of T lymphocytes. By adding the analysis of the combinatorial diversity of the V(D)J rearrangements of the IgH locus, information on all the lymphocytes (B and T) is obtained. 
     An important aspect of the invention, illustrated in the examples hereinafter, is the possibility of identifying, by their name, the various rearrangements observed. According to one preferred implementation, step C) of the method comprises a step of processing the data obtained by separating the amplicons according to their size, said processing being carried out by means of a computer and making it possible to assign, to each amplicon observed, the name of the corresponding V(D)J rearrangement. More preferably, the data processing also integrates the intensity of the signal of each of the amplicons observed, in order to quantify the relative frequency of the corresponding V(D)J rearrangement. 
     This makes it possible to describe a signature of an immune diversity by classifying the VDJ rearrangements in order of intensity or in order of contribution within the immune repertoire observed. This classification of the rearrangements corresponds to a signature of the immune repertoire at an instant “t” in a sample. 
     In particular, the method of the invention can be such that step B) comprises the acquisition of the data concerning the size of the amplicons and, for each one, the intensity of the signal, and step C) comprises the following steps: 
     (i) identification of each amplicon, by determining the V(D)J rearrangement to which it corresponds, as a function of its size; 
     (ii) from the intensity of the signal of each amplicon, determination of the proportion of starting genomic DNA having the corresponding V(D)J rearrangement; 
     (iii) presentation of the results in the form of a three-dimensional graph showing the V x  genes or the families of V x  genes along one axis, the J y  genes along another axis, and the frequency of the V x J y  rearrangements along the third axis. 
     If the molecular diversity is also measured, for example by carrying out a real-time measurement of the amplifications by multi-n-plex PCR, the method makes it possible to measure an overall immune diversity by taking into account the measurement of the combinatorial diversity and of the molecular diversity. 
     The present invention also relates to a method for determining, in vitro, the degree of immunodeficiency of an individual, comprising the following steps: 
     A) using a biological sample from said individual, performing a lymphocyte count; 
     B) using the same sample or another sample originating from the same individual at the same time, determining the degree of combinatorial diversity of the repertoire of lymphocytes of said individual, by implementing a method as described above; 
     C) combining the data obtained in steps A) and B). 
     This method may comprise an additional step of interpreting the combination obtained in step C), from the viewpoint of a graph which assigns a level of risk at least to zones (i) to (viii), and preferably to zones (i) to (xii) hereinafter: 
     (i) low count (&lt;1000 Ly/μL) and low V-J combinatorial diversity (&lt;70% for TCR diversity and &lt;60% for immunoglobulins diversity): high risk of infection (including viral reactivation) and/or cancer development, possibly leading to death; 
     (ii) low count (&lt;1000 Ly/μL) and low TCR V-J combinatorial diversity, with normal immunoglobulins (BCR) diversity (&lt;70% for TCR diversity and &gt;60% for immunoglobulins diversity): high risk of infection (including viral reactivation), and/or cancer development, possibly leading to death; 
     (iii) low count (&lt;1000 Ly/μL) and low BCR V-J combinatorial diversity with normal TCR V-J combinatorial diversity (&gt;70% for TCR diversity and &lt;60% for immunoglobulins diversity): medium risk of infection (including viral reactivation), and/or cancer development, possibly leading to death; 
     (iv) low count (&lt;1000 Ly/μL) but normal V-J combinatorial diversity (&gt;70% for TCR diversity and &gt;60% for immunoglobulins diversity): low risk of infection (including viral reactivation) and of cancer development; 
     (v) normal count (1000-3500 Ly/μL) and low V-J combinatorial diversity (&lt;70% for TCR diversity and &lt;60% for immunoglobulins diversity): medium risk of infection (including viral reactivation) and/or cancer development, possibly leading to death; 
     (vi) normal count (1000-3500 Ly/μL) and low TCR V-J combinatorial diversity with normal BCR V-J combinatorial diversity (&lt;70% for TCR diversity and &gt;60% for immunoglobulins diversity): medium risk of infection (including viral reactivation) and/or cancer development, possibly leading to death; 
     (vii) normal count (1000-3500 Ly/μL) and low BCR V-J combinatorial diversity with normal TCR V-J combinatorial diversity (&gt;70% for TCR diversity and &lt;60% for immunoglobulins diversity): medium risk of infection (including viral reactivation) and/or cancer development, possibly leading to death; 
     (viii) normal count (1000-3500 Ly/μL) and normal V-J combinatorial diversity (&gt;70% for TCR diversity and &gt;60% for immunoglobulins diversity): the immune repertoire is similar to the one of the general population and can be considered as “healthy”; 
     (ix) count above normal (&gt;3500 Ly/pl) and low V-J combinatorial diversity (&lt;70% for TCR diversity and &lt;60% for immunoglobulins diversity):lymphoproliferative risk; 
     (x) count above normal (&gt;3500 Ly/μL) and low TCR V-J combinatorial diversity with normal BCR V-J combinatorial diversity (&lt;70% for TCR diversity and &gt;60% for immunoglobulins diversity): T cell lympho-proliferative risk; 
     (xi) count above normal (&gt;3500 Ly/μL) and low BCR V-J combinatorial diversity with normal TCR V-J combinatorial diversity (&gt;70% for TCR diversity and &lt;60% for immunoglobulins diversity): B cell lympho-proliferative risk; 
     (xii) count above normal (&gt;3500 Ly/pl) and normal V-J combinatorial diversity (&gt;70% for TCR diversity and &gt;60% for immunoglobulins diversity): medium lymphoproliferative risk. 
     Of course, in what precedes, the “level of risk” will be appreciated by the clinicians according to their practice. The “low” risk is lower than the “medium” risk, itself lower than the “high” risk, which does not mean that a patient with a low risk of infection will never develop an infection. However, a patient with a high risk of infection is not only more likely to develop infections, but theses infections will probably be more numerous and more serious than those encountered by a patient with a lower risk. 
     This determination of the degree of immunodeficiency of an individual (based not only on the count but also on the measurement of lymphocyte diversity) is essential for implementing personalized medicine, since a patient having an immune diversity of less than 40% is considered to have a diversity deficiency which implies an increased risk of mortality not only by infection, but also due to neoplasms or other causes. This method therefore makes it possible to determine, for a patient, the risk of mortality of said patient. 
     Advantageously, the clinician may conduct an immuno-logical follow-up of his or her patient, making it possible in particular to identify whether the treatment administered has consequences that are too severe on the immune diversity of the patient, inducing a risk of infection and/or of cancer development that in some cases can lead to death. In this case, the clinician may adjust the treatment (change of molecule, of dose, of frequency, addition of supplementary antibiotic treatments, of immunostimulation with interleukin IL7, IL2 or the like, etc.) in order to reduce this risk. 
     The invention therefore also relates to the use of the method above, for aiding a clinician in making his or her therapeutic choices, through the choice of a treatment suitable for the level of risk of infectiousness and of mortality of a patient. Thus, a patient who is in zone (iv) defined above can, a priori, withstand an immunosuppressive treatment (for example, chemotherapy+powerful monoclonal antibodies), whereas, conversely, a patient who is in zone (i) has a very fragile “immune shield” (and therefore a high risk of infection and/or of cancer development that in some cases can lead to death), and should therefore be treated with medicaments that are less immunosuppressive. The patients in zones (ii) and (iii) are in an intermediate situation. 
     In one preferred implementation of a method for determining, in vitro, the degree of immunodeficiency of an individual, as described above, step B) comprises determining the degree of combinatorial diversity of the repertoire of T lymphocytes and of B lymphocytes of said individual. In this situation, it is advantageously possible to examine the data obtained by means of a three-dimensional graph showing the degree of immunoglobulin diversity on one axis, the degree of TCR diversity on another axis, and the lymphocyte count on a third axis. 
     It is important to note that the two-dimensional and three-dimensional graphs described above can be used by replacing the lymphocyte count by any other biological marker relevant to illustrate the immunological status of a given individual, and/or by measuring the immunoglobulin diversity (IGH diversity) and/or TCR diversity(TRB diversity) by any appropriate method such as, of course, the multi-n-plex method described above for measuring the combinatorial diversity, but also by NGS methods such as those described in U.S. Pat. Nos. 8,236,503 and 8,507,205, etc. Of course, the thresholds mentioned above for defining zones to which a level of risk can be assigned depend from the technology used to measure the diversity. 
     The present invention hence pertains to a method of visualizing an immunological status of an individual, comprising the following steps:
         A) using a biological sample from said individual, measuring a first biological marker linked to the immunological status;   B) using the same sample or another sample taken from the same individual at the same time, determining the degree of immunoglobulin and/or TCR diversity of said individual;   C) combining the data obtained in steps A) and B) and representing the result (i) in a two-dimensional graph showing the degree of immunoglobulin or TCR diversity on one axis and the first biological marker on the second axis, or (ii) in a three-dimensional graph showing the degree of immunoglobulin diversity on one axis, the degree of TCR diversity on another axis, and the first biological marker on a third axis.       

     As mentioned above, the first biological marker can be any relevant marker linked to the immunological status. In particular, this marker can be selected from the group consisting of lymphocytes countand the count of any sub-population(s) of immunological cells, such as:
         Lymphoid cells: Acute lymphocyte count, Treg, Th17, NKT and NK cells;   Myeloid cells: Granulocytes such as dendritic cells, Macrophages, myeloid derived suppressor cells (MDSC), basophil, mast cells, Neutrophiles, eosinophil.       

     This method can be of particular interest for following up the immunological status of an individual, by visualizing, in a same graph, the immunological status of the same patient, at two or more time points; advantageously, the points of the graph representing two consecutive immunological statuses of said patient are linked, for example by an arrow starting at one point and ending at the point representing the following measured status. Hence, at one glance, a skilled artisan can see the evolution of the immunological status of a patient. 
     To render this graph (either 2D or 3D) even more easy to read and understand at first glance, the arrows can advantageously be colored, so that:
         if the arrow points to a point representing an immunological status which is better than its starting point, the arrow is drawn in a first color symbolizing an improvement of the patient&#39;s immunological status (for example, green);   if the arrow points to a point representing an immunological status which is worst than its starting point, the arrow is drawn in a second color symbolizing a degradation of the patient&#39;s immunological status (for example, red); and   in intermediate cases, the arrow is drawn in a third color (for example, orange or yellow).       

     When performing the above methods, the biological sample can advantageously be selected from the group consisting of a whole blood sample, a blood clot, PBMCs and a tissue biopsy. 
     Another aspect of the invention concerns a method of monitoring the change in the diversity of the repertoire of T and/or B lymphocytes of an individual,comprising the following steps: 
     A) measuring the diversity of the repertoire of lymphocytes of said individual, by implementing a method as described above, using two samples from said individual, taken at two different dates; 
     B) comparing the two samples by evaluating:
         (i) the number S of rearrangements observed in the two samples;   (ii) the number A of rearrangements observed in the more recent sample but not in the older sample;   (iii) the number D of rearrangements observed in the older sample but not in the more recent sample;   (iv) the number Z of rearrangements which are not observed in either of the samples.       

     An example of interpretation of this graph is shown in example 11 hereinafter. This method can also be used to compare 2 samples from different individuals, for example in order to compare a donor and a recipient in the case of a transplant. 
     The present invention also relates to a kit for implementing one of the methods described above, comprising at least one combination of primers as defined in this text, and reagents for carrying out PCRs. 
     Among the reagents for carrying out PCRs, a kit according to the invention will preferably comprise a polymerase having the following characteristics: 
     (i) it is capable of amplifying fragments of several tens of kb; 
     (ii) its elongation rate is at least 1 kb/minute; 
     (iii) its robustness is such that it does not introduce more than one error per kb, on average. 
     Advantageously, a kit of the invention will comprise a multiwell plate in which each well contains a different combination of primers, in freeze-dried form or in a liquid phase. Preferably, this multiwell plate comprises all the combinations of primers necessary for amplifying at least 50%, 60%, 70%, 80% or even 95% of the V-J rearrangements of at least one locus chosen from the TRA, TRB, TRG, TRD and IgH loci. 
     Another aspect of the invention concerns the use of a method or of a kit as described above, for studying the setting up and/or the quality of the TCR and/or IgH repertoire of a humanized transgenic animal and/or of a culture of lymphocytes. This makes it possible in particular to verify the quality of an immune repertoire subsequent to a cell culture, for example in order to verify that the cell culture remains suitable for testing molecules or for studying biological mechanisms. In the case of monoclonal or oligoclonal T or B lines, this makes it possible to verify that the line(s) is (are) indeed the clone(s) previously identified, and thus to detect any contamination or labeling error on a tube with to run an experiment. Another important application is that of controlling quality during the production of lymphocyte cultures (regulatory T lymphocytes, for example, etc.) before reinjection (for therapeutic purposes). 
     The present invention also relates to the use of a method or of a kit as described above, for screening for therapeutic molecules in vitro. Examples of applications are described hereinafter. 
     In particular, the methods and the kits of the invention can be used to carry out a method of evaluating the efficacy of a vaccine protocol, comprising the steps of: 
     A) measuring the amount and the diversity of lymphocytes before and after said vaccine protocol; 
     B) comparing the measurements carried out in step A); and 
     C) interpreting the results, a decrease in lymphocyte diversity of at least 10%, preferably of at least 15%, after vaccination, indicating that the vaccination protocol was effective. 
     According to one preferred implementation of this method, the amount of regulatory T lymphocytes before and after vaccination is also measured in step A). In this case, interpretation step C also takes into account the change in the number of regulatory T lymphocytes, a decrease by a factor of ≧2 in the number of regulatory T lymphocytes following the vaccination indicating that the protocol was effective. 
     The invention also relates to a method for comparing the efficacy of two vaccine protocols, comprising the steps of: 
     A) measuring, on two groups subjected to a vaccination with two different protocols, the amount of regulatory T lymphocytes and the immune diversity, before and after vaccination; 
     B) comparing the results group-to-group, in which the most effective protocol is that which induces the greatest decrease in regulatory T lymphocytes and/or the greatest decrease in lymphocyte diversity. 
     In addition to the above arrangements, the invention also comprises other arrangements which will emerge from the experimental examples below and from the attached figures. 
     EXAMPLE 1 
     Choice of the Position of the Primers That Can be Used in the Context of the Invention 
     Oligonucleotide Selection Criteria 
     The primers that can be used for implementing the method of the invention are chosen according to 1) their thermodynamic properties (determined on the basis of algorithms conventionally used by those skilled in the art for identifying the ability of oligonucleotides to bind to their target sequence, in particular according to the number of hydrogen bonds); 2) their compatibility with the other primers used in the same tube, both in thermodynamic terms and in terms of the inability of the various primers to hybridize with one another; and 3) their respective position which makes it possible to obtain amplicon sizes that can be resolved. 
     The term “resolved” should be understood to mean that the amplicons can be observed individually, subsequent 
     to size-separation thereof by means of an electro-phoresis method or any other method. When the sizes of certain amplicons are too close, it is not possible to discern them distinctly with separation conditions that are compatible with the separation for “resolving” all the other amplicon sizes. This case is in the minority and identified. It can be solved, for example, by using labeled primers. 
     The oligonucleotides are defined herein by giving, in addition to their sequence, their position in the locus and also their size, in number of bases. 
     For the V genes, the oligonucleotides are oriented in the direction of transcription, they are called “SENSE”; they are complementary to the noncoding DNA strand. 
     For the J genes, the oligonucleotides are called “ANTISENSE”; they are complementary to the coding DNA strand and reverse (they are also referred to as being in the 3′→5′ direction). 
     Primers Specific for V Genes 
     For the oligonucleotides specific for the V genes, the position is given according to the end of the V gene, i.e. the last base before the RSS. This position corresponds to the distance (including the oligonucleotide) between the 1 st  base of the oligonucleotide and the last base of the V gene.
         Example of position of the oligonucleotide for the TRBV gene family: if the distance is n bases from the end of the V gene and the size of the oligonucleotide is t bases, the oligonucleotide begins n bases upstream of the end of the gene (counting the last base) and ends n−t+1 bases from the end of the V gene.       

     The oligonucleotides were selected in such a way as to hybridize with the largest possible number of members of a V family. Two situations can be described concerning the number of V oligonucleotides necessary for monitoring an entire V family:
         Case 1: existence of a region of 100% homology between all the members of a family. In this case, it is possible to find, by performing a sequence alignment, a region 100% common for all the members of the V family in question and meeting the oligonucleotide selection criteria specified above. In this case, only one V oligonucleotide is necessary for monitoring all the members of the family.   Case 2: a region of less than 100% homology. In this case, the largest region (in terms of number of bases) which meets the selection criteria is selected, and all the oligonucleotides corresponding to this position that are necessary for monitoring all the members of the family are designed. Example: for a family of 5 members having a region of 100% homology for 3 members, the other 2 members being different from one another in this region. In this case, a total of 3 different oligonucleotides corresponding to the same position are designed for monitoring all the members of this family. Three subcases are then possible:
           The V oligonucleotides chosen at this position are thermodynamically compatible with one another. In this case the n V oligonucleotides (in the example above, 3 oligonucleotides) are grouped together in the same PCR tube. Since all these oligonucleotides, even if they have a few different bases, are designed at the same position, the amplicons will be of the same size.   The V oligonucleotides are not sufficiently thermodynamically compatible and they cannot be placed in the same PCR reaction since this would pose dimer problems. In this case, 2 or n PCRs can be carried out in different tubes, in order to specifically monitor the V members for which the primers are incompatible with the others.   A particular (rare) case exists in which the V genes of the same family do not have the same size. This is due to the fact that the intron of one or n member(s) of a V family has (have) a size that is different than that of the other members of said V family (observation: there is only one intron per V gene). This situation is not a problem if the V oligonucleotide is designed downstream of this “region of different size”. If this is not possible, the solution implemented consists in separating the 2 or n oligonucleotides in 2 or n PCRs.   
               

     Primers Specific for J Genes 
     The position of a primer specific for a J gene is given by indicating its distance relative to the start of the J gene i.e. the 1 st  base of the segment of J gene (coding sequence), after the RSS. This position is located downstream of the start of J and corresponds to the distance (including the oligonucleotide) between the 1 st  base of the J gene and the 1 st  base of the oligonucleotide (i.e. the base at the 5′ end of the primer).
         Example of position of the oligonucleotide for the TRBJx gene family: the distance is n bases from the start of J, the size of the oligonucleotide is t bases. Therefore, the region of hybridization of the primer (on the coding strand) ends at the n th  base of the J gene or downstream of the start of the J gene and starts n−t+1 bases from the start of J.       

     Recovery of the Sequences of the TCR and Ig Loci 
     Several methods are possible for obtaining the sequences. Two possibilities are described hereinafter. 
     1 st  Possibility 
     The 1 st  possibility requires logging on to the European internet site “Ensembl Genome Browser” http://www.ensembl.org and researching the locus of interest: after having chosen the species (human, mouse, etc.), it is necessary to click on the chromosome of interest, for example chromosome 14 for the TRA locus. It is then necessary to indicate, in the block provided for this purpose, the number indicating the start of the chromosomal region (for example: 21158000) and the end of the region (for example: 22125000). The Ensembl database reveals graphically the arrangement of the TCR and Ig genes present in the locus, and those skilled in the art can export (by means of a left click on the contig concerned) the DNA sequence to the EMBL or GenBANK format with all the corresponding gene annotations. They thus have at their disposal the location of all the sequences of the TCR and Ig genes, including the sequences upstream and downstream of the latter. 
     The chromosomal regions for the various human loci to which the present invention relates are indicated hereinafter. 
     Homo sapiens TRA/TRD: locus at 14q11.2: 
     http://www.ensembl.org/Homo_sapiens/contigview?region=1 4&amp;vc start=21158000&amp;vc end=22125000 
     Homo sapiens TRB: locus at 7q34: 
     http://www.ensembl.org/Homo_sapiens/contigview?region=7 &amp;vc start=141640000&amp;vc end=142275000 
     Homo sapiens TRG: locus at 7p14: 
     http://www.ensembl.org/Homo_sapiens/contigview?region=7 &amp;vc start=38242000&amp;vc end=38385000 
     Homo sapiens IgH: locus at 14q32.33: 
     IgHV: 
     http://www.ensembl.org/Homo_sapiens/contigview?region=1 4&amp;vc start=105476000&amp;vc end=106368585 
     IgHD and IgHJ: 
     http://www.ensembl.org/Homo sapiens/contigview?region=1 4&amp;vc start=105400000&amp;vc end 105460000 
     IgHC: 
     http://www.ensembl.org/Homo_sapiens/contigview?region=1 4&amp;vc start=105120000&amp;vc end=105400000 
     Homo sapiens IgK: locus at 2p11.2: 
     IgKV (Proximal Cluster), IgKJ and IgKC: 
     http://www.ensembl.org/Homo_sapiens/contigview?region=2 &amp;vc start=88920000&amp;vc end=89480000 
     IgKV (Duplicated Digital Cluster): 
     http://www.ensembl.org/Homo_sapiens/contigview?region=2 &amp;vc start=89550000&amp;vc end=89950000 
     Homo sapiens IgL: locus at 22q11.2: 
     http://www.ensembl.org/Homo_sapiens/contigview?region=2 2&amp;vc start=20700000&amp;vc end=21650000. 
     2 nd  Possibility: 
     The 2 nd  possibility presented hereinafter requires the grouping together of all the cosmids containing the sequences of a TCR or Ig locus. To do this, we identified the list of accession numbers of the cosmids for the Ig and TCR chains, in humans and mice, using the literature as a basis (Lefrancs,  The Immunoglobulin Facts Book  2001 and Lefrancs  The T cell receptor Facts Book  2001) or else (Baum et al., 2006; Baum et al., 2004). 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 10 
               
               
                   
                   
               
             
            
               
                   
                 Human 
                   
               
               
                   
                 Locus 
                 EMBL-EBI accession number 
               
               
                   
                 TRAD* 
                 AE000658 to AE000662 
               
               
                   
                 TRB 
                 L36092 
               
               
                   
                 TRG 
                 AF159056, X08084, M12950, M12960, 
               
               
                   
                   
                 M16016 and M12961 
               
               
                   
                 IgH 
                 see Lefranc., The Immunoglobulin 
               
               
                   
                   
                 Facts Book ISBN: 012441351X 
               
               
                   
                 MOUSE 
               
               
                   
                 Locus 
                 EMBL-EBI accession number 
               
               
                   
                 TRAD* 
                 AE008683 to AE008686 
               
               
                   
                 TRB 
                 AE00063 to AE00065 
               
               
                   
                 TRG 
                 AF037352 and AF021335 
               
               
                   
                 IgH 
                 see Lefranc., The Immunoglobulin 
               
               
                   
                   
                 Facts Book ISBN: 012441351X 
               
               
                   
                   
               
               
                   
                 *Reminder: the TRD locus is located in the TRA locus. 
               
            
           
         
       
     
     From these numbers, it is possible to recover all the information on the source sequences of the loci in the “EMBL-EBI” European reference internet site (http://www.ebi.ac.uk), by carrying out a “search”, in the “nucleotide sequence” section. The “EMBL-BANK” (Europe&#39;s primary nucleotide sequence resource) results can subsequently be downloaded to the EMBL format. 
     The study of the sequences can be carried out on software such as NTI Vector®. Since the genes are annotated, their position is precisely indicated. 
     Correspondence Between the Various Nomenclatures of the Genes of the TCR and Ig Loci 
     It is important to note that the nomenclature of the genes has changed over time. In order for those skilled in the art to find their way around the nomenclatures, they have correspondence tables for the TCRs and Igs that can be found in the two books [1] Lefranc, M.-P. and Lefranc, G., The Immunoglobulin Facts Book, Academic Press, 458 pages (2001) ISBN:012441351X [2] Lefranc, M.-P. and Lefranc, G., The T cell receptor Facts Book, Academic Press, 398 pages (2001) ISBN:0124413528. This information can also be found on the IMGT site (http://imgt.cines.fr). 
     EXAMPLE 2 
     Protocol for the Use of ImmunTraCkeR Kit 
     Example on the TRB Locus 
     The amounts necessary are optimized according to the nature of the sample (cells; PBMCs; thymus extract; etc.). For a cell sample, the amount necessary for carrying out the experiment is 10 6  cells. 
     The succession of the various steps of the protocol is shown schematically in  FIG. 19 . 
     2-A. DNA Extraction 
     An extracted DNA of high purity is necessary for detecting the V-J rearrangements using the ImmunTraCkeR Kit. Those skilled in the art know which method or kit is suitable for this. In particular, those skilled in the art know that this extraction should be carried out without any EDTA or other product that may inhibit the PCR. The inventors recommend extracting the DNA using the High Pure PCR Preparation Template Kit from Roche®. 
     The recommended DNA concentration is 100 ng/μl. 
     2-B. Control of DNA Quality and Determination of the Amount 
     The absorbance of the sample at 260 nm is measured with a spectrophotometer (for example, Amersham GenQuant Pro). This measurement makes it possible to calculate the DNA concentration, the degree of extraction and the DNA/protein ratio, which gives an estimation of the quality of the DNA. 
     In addition, the degradation state of the DNA is controlled on an agarose gel and, subsequently, the DNA concentration is standardized by comparison with an actin control. 
     2-C. PCR Amplification 
     The ImmunTraCkeR Kit contains the combinations of primers (dehydrated or in liquid phase) already distributed into the tubes. The reaction mixture is prepared and distributed into said reaction tubes. 
     a) Herculase®II Fusion optimized protocol 
     Preparation of the Reaction Mixture 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 13 
               
               
                   
                   
               
               
                   
                 Component 
                 Amount per reaction 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Distilled water 
                 12.89 
                 μl 
               
               
                   
                 Herculase ®II 5X reaction buffer 
                 5 
                 μl 
               
               
                   
                 dNTP mix (10 mM) 
                 0.62 
                 μl 
               
               
                   
                 DNA template (50 ng/μl) 
                 1 
                 μl 
               
               
                   
                 Herculase ®II Fusion DNA polymerase 
                 0.5 
                 μl 
               
            
           
           
               
               
            
               
                   
                 Final volume: 20 μl 
               
               
                   
                   
               
            
           
         
       
     
     The reaction mixture is then distributed into tubes or wells, in a proportion of 20 μl in each. 
     The PCR is carried out using optimized cyclic conditions. Suggested cycling parameters for carrying out PCRs with the Herculase®II Fusion DNA polymerase, using a Primus 96+ (MWG) device, are indicated below. 
     PCR Cyclic Parameters: 
     
       
         
           
               
               
               
               
             
               
                 TABLE 14 
               
               
                   
               
               
                   
                 Number of 
                   
                   
               
               
                 Segment 
                 cycles 
                 Temperature 
                 Duration 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 1 
                 1 
                 98° C. 
                 3 
                 minutes 
               
               
                 2 
                 30 
                 98° C. 
                 20 
                 seconds 
               
               
                   
                   
                 62° C. 
                 20 
                 seconds 
               
            
           
           
               
               
               
            
               
                   
                 72° C. 
                 3 minutes 30 seconds 
               
            
           
           
               
               
               
               
               
            
               
                 3 
                 1 
                 72° C. 
                 3 
                 minutes 
               
               
                   
               
            
           
         
       
     
     Duration of PCR: approximately 4.5 hours. 
     2-D. Agarose Gel Electrophoresis 
     A 0.8% (w/v) agarose gel is prepared in a 1× TBE buffer. 
     The PCR products, mixed beforehand with a loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% Ficoll 400, in water), are loaded in a proportion of approximately 10 μl of PCR products and 2 μl of loading buffer. 
     A suitable DNA size marker is loaded onto each end of the gel. 
     A voltage is applied to the gel in a 1× TBE buffer, without recirculation of the buffer, for 1 hour 30 minutes at 250V and 120 mA. 
     The gel is stained with 40 μl of ethidium bromide diluted in 150 ml of 1× TBE buffer for 30 minutes. 
     2-E. Acquisition and Interpretation 
     The gel is placed on a UV transilluminator and the image is acquired by photography. The presence or the absence of the specific products of the PCR is recorded. 
     EXAMPLE 3 
     Analysis of the Rearrangements of All the Functional J Genes of the Beta Locus With One Given V Gene, in One Resolving Multi-2-Plex PCR 
       FIG. 2A  shows the analysis of the average GC content of the human TRBJ and TRAJ regions. The J2 region contains a very high GC content, with 60% against 40-45% on average. 
       FIG. 2B  shows the particular arrangement of the J genes of the TRB locus (in 2 distinct clusters). 
       FIG. 2C  illustrates the principle for choosing the primers, with one antisense primer close to a J cluster and a second antisense primer far from the J cluster, making it possible to position the entire J1 cluster above the J2 cluster. 
       FIG. 2D  presents an example of a result obtained by means of this method. 
     This configuration makes it possible to halve the amount of biological material necessary and by the same token to reduce the cost price of the test. The amount of time for carrying out the test is also reduced. In addition, this enables a simplified reading of the lane of the gel (or of another type of separation) since the J genes are in the order of the locus and are therefore readily identifiable. 
     EXAMPLE 4 
     Analysis of Several Loci in the Same Multi-n-Plex PCR Reaction 
       FIG. 3  illustrates the possibility of analyzing rearrangements of several loci in the same reaction, so as to reduce, by a factor of 3-4, the amount of biological material necessary for monitoring the entire immune repertoire. In this example, rearrangements of the TCRB and TCRD repertoires are observed in a single step. This makes it possible to monitor all the T alpha/beta and T gamma/delta lymphocytes. 
     EXAMPLE 5 
     Embedded Multiplex PCR 
       FIGS. 4A-4E  illustrate the principle of “embedded” multi-n-plex PCR, i.e. in which the series of amplicons obtained with the various pairs of primers are such that an amplicon obtained with a first pair of primers can be bordered by 2 amplicons obtained with a second pair of primers. 
       FIG. 4A  gives a diagram of the TRG locus. 
       FIG. 4B  shows diagrammatically the principle of resolution with an hTRGV family. 
       FIG. 4C  shows the result of a multiplex PCR on the hTRG locus, targeting the 2 J clusters with a single J primer. The experiment was carried out on HEK and CaCO cells as negative controls and on PBMCs and thymus cells as positive controls. 
     It should be noted that, for the TRG locus, it is possible to monitor 2 TRGJ clusters with just one J oligonucleotide, owing to the 100% sequence homology downstream of the J1 and J2 genes. 
       FIG. 4D  shows an example of embedded multi-2-plex PCR with two TRAJ primers. 
       FIG. 4E  shows an example of resolution of 95% of the AJ region with only 6 multi-2-plex PCRs. The position of the primers is indicated below the name of the J gene of the oligonucleotides downstream of the (start of the) J gene. This position is important. It makes it possible to be sure that the expected bands will have a size that allows them to be resolved. 
     EXAMPLE 6 
     Result of the TRBV ImmunTraCkeR Kit in Multi-2-Plex PCR 
       FIGS. 5 and 6  show the various bands obtained after the migration, on an agarose gel, of all the PCR products obtained by multi-n-plex PCR.  FIG. 5  shows a diagrammatic representation of the theoretical result obtained with the human TRB Immun TraCkeR kit (the representation is similar in other species: rat, mouse, monkey, etc.). Each column corresponds to one TRBV family, each band corresponds to a given V-J rearrangement. The TRBV genes were studied in the following order: BV2, BV3, BV4, BV5, BV6, BV7, BV9, BV10, BV11, BV12, BV13, BV14, BV15, BV16, BV18, BV19, BV20, BV24, BV25, BV27, BV28, BV29, BV30.  FIG. 6  shows the corresponding experimental results obtained in duplicate (loaded side by side) with three types of samples: gDNA extracted from thymus, gDNA extracted from PBMCs under lymphopenic conditions and, finally, a pool of DNA of 4 T lines each comprising one or two TRBV-J rearrangements. 
     Having all the PCRs of the 24 TRBVs side by side allows exhaustive detection of the TRBV genes over all the BJ segments. 
     It is also possible to add (as an option) a loading and/or PCR reproducibility marker to each of the lanes (observation: these 2 reproducibility markers are not essential). Advantage sought: improving the standardization of the signal between the bands. 
     This figure illustrates the fact that the invention makes it possible to evaluate the quality of an immune repertoire by measuring both the combinatorial diversity of an image of the immune repertoire (calculation of the sum of the bands obtained) and also the intensity of the signal of all of the bands (calculation of the sum of all the signals of the amplicons of the image). In addition, the name of each V(D)J rearrangement present or absent is identified (as a function of its position in the image). The column gives the name of the V; the size of the amplicon gives the name of the J. The intensity of the signal detected gives the respective proportion of each V(D)J rearrangement. Overall, this therefore makes it possible, in a single step, to have a tool which both measures the diversity (useful for measuring the precise degree of immunodeficiency of a patient) and identifies the name of the rearrangements (therefore the TCR or Ig marker of a lymphocyte) involved in a pathological condition (leukemia, lymphoma, GVHD, etc.) or having reacted by increasing (cell multiplication) or by decreasing following a treatment. 
     EXAMPLE 7 
     Study of D-J Rearrangements by PCR Clustering 
       FIGS. 7A-7B  show the result of a test for detecting incomplete D-Jβ rearrangements which is both exhaustive and resolvent (lanes A: D1 rearrangements with the J1 cluster and the J2 cluster. Lanes B: D2 rearrangements with the J2 cluster). This test makes it possible to characterize a clone by specifying the name of the rearranged D and J genes. 
     In comparison, Biomed-2 proposes only a signal of ON/OFF type: the presence of a monoclonal population is actually detected, but this population is not characterized at the combinatorial level. It is not possible to differentiate between the rearranged V and J genes. This is because the size of the PCR products of this test varies only by a few bases, making it impossible to identify the V family in question, or the rearranged J gene. The method of the present invention therefore makes it possible to provide a higher degree of information. 
     Analysis of the Results: 
     Part A: The number of expected bands is clearly observed on positive controls (PBMCs and thymus). The bands corresponding to the rearrangements of the D1 gene with the J1.1 and J1.2 genes are fused since the resolvent limits of the technology used do not allow the separation of bands of which the size difference does not exceed 10% of the size of the largest band. Sequencing of this band, or the use of labeled primers, would be necessary for validation of this observation. 
     Two very strong bands appear on the negative control. These bands are not nonspecific, but correspond to the germinal DNA amplification: the characteristics of the locus coupled with the ability of the technology to amplify large fragments mean that it is not necessary for there to be a rearrangement in order to observe a product in this precise case. These two bands constitute a very good internal control for the presence and for the quality of the DNA tested, and also for the efficiency of the enzyme. 
     Part B: The method makes it possible to very rapidly characterize the intermediate rearrangement of T (or even B) lymphocyte lines. In the example above, the incomplete D1-J1.3 rearrangement for the T cell line called JURKAT, the incomplete D1-J2.5 rearrangement for the MOLT4 T line and the incomplete D2-J2.3 rearrangement for the HUT-78 T line were characterized without the need for further sequencing. 
     It is important to note that the incomplete D-J and D1-D2 rearrangements are nonfunctional, but, in certain cases, represent the only biological marker for identifying lymphoproliferation (B or T lymphoma or leukemia). 
     EXAMPLE 8 
     Examples of Representation of the Results of Mapping 
       FIGS. 8A-8D  illustrate a method for grouping together all the data from analysis of the immune repertoire on a single page, including in particular the count, and/or the diversity of the sample, and/or the intensity of the signal, and/or a comparison with a reference diversity originating from another patient or from the same patient, information for identifying that the patient is suffering from lymphopenia by comparing the % diversity obtained with a reference repertoire, and/or information on the number of clones detected in the image, and/or a two-dimensional and/or three-dimensional representation graphic, and/or the list of all the V-J rearrangements classified by a decreasing amount of amount of signal detected, and/or representativeness in the image. The method, in its steps of analysis, thus makes it possible: 
     1—to compile the information collected regarding the clinical history of the patient and the biological history of the sample (results of counts, cytometries, sampling conditions, etc.); 
     2—to comb the data using statistical methods and to correlate the results of analyses of the immune repertoire (combinatorial diversity, or other approach) with the clinical and biological data. It is in particular possible to classify all the V(D)J rearrangements in order of frequency of detection (intensity of the signal of the amplicon). This order varies from one individual to the other according to the treatments and infections encountered by the lymphocyte repertoire of said individual. This makes it possible to possess the signature of the immune repertoire of an individual at an instant T. This signature may be the biological marker for a pathological condition, such as autoimmune diseases, allergies, leukemias, lymphomas, etc. 
     N.B. It is important to note that this approach can also be compatible with other approaches for analyzing the immune repertoire (all approaches for analyzing the junctional diversity, pairing diversity, somatic-mutation diversity, etc.). 
     EXAMPLE 9 
     Lympocyte Count/Diversity (LCD) 
     The lymphocyte count performed during a CBC or during labeling in cytrometry gives the number of lymphocytes in a sample. This number is used to verify that the patient does not show any immunodeficiency. The range of “normality” is conventionally between 1000 and 3200 lymphocytes/μL of blood. Below 1000, the patient is considered to be slightly immunodepressed; below 450, severe immunosuppression is involved. Conversely, above 3200, the patient is considered to be potentially at risk of lymphocyte expansion. There are two weak points in this approach: the first is the size of the range itself, which corresponds to a factor of 3 between the minimum and maximum values. The second point, which is even more bothersome, is that this count does not prefigure the real diversity of the immune repertoire of the patient ( FIG. 9 , graph 1). The present invention makes it possible to couple a conventional count with a measurement of the V-J combinatorial diversity ( FIG. 9 , graph 2). 
     This can in particular be used for selecting patients in the context of clinical trials, in order to test medicaments on a homogeneous population, making it possible to interpret the results. This also makes it possible to give a prognosis of a patient&#39;s infectious risk, and therefore to practice personalized medicine, by adjusting the immunosuppressiveness of a treatment to a patient&#39;s level of risk of mortality owing to infection. 
     The graph in  FIG. 9  distinguishes in particular the following populations: 
     1. Low count (&lt;1000 Ly/μL) and low combinatorial diversity (&lt;40%): The patient is an immunosuppressed patient. 
     Action to be taken: Do not include this patient in the clinical study. Have this patient monitored by a hematologist. 
     2. Low count (&lt;1000 Ly/μL) but normal V-J combinatorial diversity (&gt;65%): the patient has a low level of circulating lymphocytes compared with the other populations of immune cells, but the quality of said patient&#39;s specific immune defense is not especially called into question. 
     Action to be taken: If the study is a study concerning elderly individuals, it would be interesting to include an arm of patients having this characteristic. 
     3. Normal count (1000-3200 Ly/μL) and low combinatorial diversity (&lt;40%): there are “gaps” in the immune repertoire. This lymphocyte count, which appears to be normal, hides an immunodeficiency condition that may be associated with one or more clonal expansions. The vaccine efficacy may be called into question. 
     Action to be taken: We recommend not including this patient in the clinical study. Have this patient monitored by an oncologist-hematologist. 
     4. Normal count (1000-3200 Ly/μL) and normal diversity (&gt;65%): the immune repertoire is healthy. 
     Action to be taken: The patient can be included in the clinical study. 
     5. Count above normal, and low diversity: high-risk zone, the sample contains only one or a few clones of lymphocytes. 
     Action to be taken: Do not include this patient in the clinical study. Have this patient monitored by an oncologist-hematologist. 
     6. Count above normal, but normal diversity: generalized lymphocytosis, the individual&#39;s specific immune system is overactivated, but no element implies a monoclonal expansion that may be connected to a leukemia or a lymphoma. 
     Action to be taken: Do not include this patient in the clinical study. Have this patient monitored by an oncologist-hematologist in order to monitor the progression of the lymphocytosis. 
     This novel count technique, called “lympocyte count/diversity”, which couples the analysis of the immune repertoire with the count (whatever the counting method) of the number of lymphocytes of the patient, is therefore much more informative than the simple lymphocyte count. It makes it possible in particular to avoid the paradox of the cell count which at times gives the impression that a patient has a lymphocyte number considered to be normal, but who, in reality, exhibits T or B clones and therefore a low immune diversity (zone 3). Conversely, this makes it possible to be sure that patients having a low count nevertheless have a “correct” immune diversity (zone 2) enabling them to defend themselves against infections and therefore making it possible not to impose on them medical monitoring that is as laborious as for patients who are really immunodepressed, i.e. patients with a low count and a low diversity (zone 1). In addition, this makes it possible to distinguish between at least 2 categories of patients having a very high lymphocyte count. The first category (zone 5) has a low diversity which is associated with the presence of one or more clones, that may be due to a leukemia, a lymphoma, GVHD, an autoimmune disease, an allergy, a response to a vaccine or any other therapy and immunotherapy. The 2 nd  category (zone 6) corresponds to a lymphocytosis, i.e. an expansion of the majority of the immune repertoire. 
     EXAMPLE 10 
     Strategy for Personalized Diagnosis in Oncology-Hematology 
       FIG. 10  presents a decision tree in oncology-hematology using LCD. 
     According to the scheme presented, two sets of primers are used sequentially (the test with the 2 nd  set being optional) to detect the VJ and DJ rearrangements of the TRB. The primers of the 2 nd  set are shifted compared with those of the 1 st  set, in order to avoid allowing a clone to escape because of a polymorphism having appeared at the site of hybridization of the corresponding primer, or of a somatic hypermutation, etc. 
     This procedure makes it possible to perform a diagnosis with respect to the level of risk of lympho-proliferation and, at the same time, the level of risk of immunodeficiency (to be associated with the risk of infection). 
     EXAMPLE 11 
     Comparison of the Lymphocyte Diversity of Two Samples 
       FIG. 11  shows a graph which makes it possible to compare two immune repertoires in order to identify the similarities or differences that may exist. Given below are the order of reading and the description of each component, and also a concrete example of the interpretation of the results. 
     The region S for “stable” represents the number of rearrangements observed in the two samples. The zone A for “appeared” represents the number of rearrangements observed in sample 2 but not in sample 1. The zone D for “disappeared” represents the number of rearrangements which are observed in sample 1 but not in sample 2. Finally, the zone Z for “never seen” represents the number of rearrangements which are observed neither in sample 1 nor in sample 2. 
     Interpretation: the high number of rearrangements observed in common (184) in the two samples indicates that the two repertoires appear to be identical. 
     Representing, on one graph, the sum of the appearances, amplification A, disappearance D, the nondetection Z and the detection S (for stable) of all the rearrangements between two immune mappings makes it possible, in one step and very visually, to determine whether a patient is undergoing reconstitution (there will be a lot of A and a low D) or whether said patient is becoming oriented toward an immunodeficiency phase (there will be a lot of D and a low A), or, finally, whether the repertoire is stable between the two mappings (there will be a lot of S). 
     Moreover, the method described here makes it possible, by relating the number of rearrangements that have appeared or disappeared to the time elapsed between the taking of the two samples, to obtain an indication regarding the speed of reconstitution or of reduction of a repertoire. This makes it possible in particular to compare the stimulant effect or, conversely, the immunosuppressive effect of a treatment. 
     EXAMPLE 12 
     Early Detection of (Oligo)Clonal Lympho-Proliferation by Quantitative Multi-n-Plex PCR 
       FIGS. 12A-12C  show diagrammatically a particular embodiment of the methods of the invention, in which the multi-n-plex PCRs are monitored in real time, in order to detect the presence of lymphoproliferation before any (optional) step of separating the amplicons by electrophoresis. 
     The PCR amplification is carried out in a real-time quantitative PCR machine, using, for example, the protocol described in example 2 above, with in addition a fluorescence measurement being carried out at each amplification cycle. 
     A specific reaction mixture, compatible both with the quantitative PCR and with the multi-n-plex PCR, was developed for this. The polymerase used is a long PCR enzyme such as HerculaseII or IProof. The major problem for setting up this reaction mixture is that SYBR green modifies the migration of gDNA in a nonlinear manner. The migration bias is in part proportional to the amount of SYBR green used, and in part dependent on the amount of the amplicon. 
     In the present case, the high degree of multiplexing and the variations in intensity (frequency) between the amplicons make it difficult to develop the real-time PCR. 
     The inventors determined the amount of SYBR green sufficient to have enough fluorescent signal for the qPCR ( FIGS. 12A and 12B ): the reaction uses as a base the same reaction mixture as that presented above, with, in addition, SYBR green in an amount greater than 0.4×, final concentration, in a reaction volume of 25 μl (i.e. 1 μl at 10× initial concentration) and less than 2×, final concentration, with preferably a 1× final concentration. This amount is considered to be a maximum since, if this amount is too large, the SYBR green causes a bias in the migration, not to mention the inhibition of multiplex PCR which was observed if the amount is greater than 1.5×, final concentration. 
     In the cases where the multi-n-plex PCRs are carried out with one primer specific for a V family and at least two primers specific for the J genes, this step, represented in graph A of  FIG. 12C , makes it possible to detect the presence of a predominant V family (the signal detected corresponds to the sum of all the V-J rearrangements of the V family studied, of the Q-PCR tube in question). 
     There are several types of expected results:
         DIVERSIFIED IMMUNE REPERTOIRE: In a healthy thymus or PBMC sample, using 50 ng of gDNA per Q-PCR, all the V families are generally detected using 20 cycles and up to a maximum of 27 cycles.       

     In a sample containing no lymphocyte, no signal is detected between 20 and 27 cycles.
         REPERTOIRE COMPRISING ONE or MORE PREDOMINANT T OR B CLONE(S): In a sample containing predominantly one V-(D)-J clone, the curve corresponding to this V-gene family emerges between 20 and 27 cycles, but the curves corresponding to the other families are detected beyond 27 cycles. This makes it possible to distinguish a V family predominantly represented in a sample.       

     Similarly, if n V families are present in large amount in the sample, we detect n curves in the 20-27-cycle window, and the other V families are detected later, &gt;27 cycles, or even are not detected at all. 
     This makes it possible to have, in real time and in less than 2 hours, a diagnosis of lymphoproliferation with respect to 1 V family at the genomic level, using the multi-n-plex PCR technique. 
     Graph B of  FIG. 12C  illustrates the optional step of analyzing the melting curve. This step makes it possible to confirm the presence of a predominant amplicon in a PCR tube in one melting curve phase: increase in temperature from 40° C. to 95° C. (temperature for total dehybridization of the DNA). During this phase, the fluorescence in the tube is measured continually. If the curve contains several peaks of similar sizes, this means that there is not a predominant amplicon; if, conversely, one predominant peak is observed, this supports the fact that an amplicon is predominant in the PCR tube in question. 
     Graph C of  FIG. 12C  shows schematically the measurement of the molecular diversity. This step allows an additional confirmation of the presence of a predominant amplicon in one PCR tube through the measurement of the molecular diversity produced by the combination between the junctional diversity (CDR3), the combinatorial diversity (V-J) and the diversity derived from the somatic hypermutations. 
     Briefly, after having brought the temperature very rapidly down to 30° C. or below, this step consists in measuring the rate of rehybridization of the amplicons at constant temperature in one PCR tube, by measuring the re-emission of fluorescence. 
     In the case of a large “molecular” diversity, the number of different amplicons in one PCR tube is high and the rehybridization of said amplicons is slow(of the order of several couples of seconds, or even minutes) (solid curve). If, conversely, there is only one predominant amplicon (with one given V-J rearrange-ment, one given CDR3 region and given somatic hyper-mutations), the rehybridization of this amplicon is rapid (of the order of a second), which then produces a more vertical curve, such as that represented as dots. 
     In summary, this rehybridization step can be informative for measuring the order of magnitude of the “molecular” diversity of a sample, without the need to migrate the PCR products. The greater the molecular diversity, the smaller the sum of the director coefficients of the curves for each V family. 
     Overall, the 3 steps A/B/C make it possible to use the properties of the Q-PCR for identifying the presence of one or more overrepresented V families, without migrating the multi-n-plex PCR product. 
     However, it is not possible to determine the name of the J gene overrepresented, nor to measure the combinatorial diversity. If the scientist wishes to have this additional information, he or she must separate the PCR products and analyze the intensity of the bands corresponding to each of the rearrangements(graph D of  FIG. 12C ). 
     Graph E of  FIG. 12C  shows a graphic summary of the count as a function of the combinatorial and molecular diversity: if the lymphocyte count of the sample is known (measured independently of this experiment by conventional counting or by cytometry), it is possible to produce a three-dimensional graph with the V-J combinatorial diversity (by measuring the sum of the V-J rearrangements detected) and the molecular diversity (by measuring the sum of the director coefficients of the slopes of the V-gene families). Finally, this method makes it possible to obtain a better characterization of a patient, according to the diversity of the immune repertoire thereof. 
     In conclusion, this method makes it possible to monitor, with an unequalled degree of finesse, the change in immune diversity following a treatment. It is in particular possible to diagnose a degree of immuno-deficiency very early. 
     EXAMPLE 13 
     Measurement of the Efficacy of a Treatment 
       FIG. 13  presents two examples of analysis of the IgH and TCR repertoires at various times, in order to monitor the change in these repertoires in patients, in response to a treatment. 
     In the case of a B-cell chronic lymphoid leukemia (B-CLL), this pathological condition is diagnosed by identifying a strong signal for one or only a few B clones. The resolvent approach developed by the invention makes it possible to identify the name of the V and J gene, without needing to sequence the PCR product. This is particularly advantageous for monitoring the residual disease.  FIG. 13  presents two situations: one prognosis which is positive (patient 1), the other being negative (patient 2). Specifically, if the treatment is effective (responding patient), the test measures an increase in the IgH combinatorial diversity, and also a stability, or even an increase, of the chains of TCRb and TCRg. Conversely, for the nonresponding (NR) patients, the diversity of one repertoire, or even of the 3 repertoires, decreases. The patient is more immunodepressed (immunosuppressed) after the treatment. 
     In the present case, the graphs are the result of the measurements of combinatorial diversity of the IgH, TCRb and TCRg chains. 
     These results show how this approach makes it possible to have the results of several tests in a single step starting from a single sample of less than 1 ml of blood: diagnosing CLL, identifying which B or T population originates from the lymphoproliferation, identifying the clone(s) involved by virtue of the V-J rearrangement thereof in order to be capable of monitoring it between various organs, and, where appropriate, finding the origin of the pathological condition. Moreover, the characterization of the predominant clone(s) enables longitudinal monitoring of the pathological condition, making it possible, in the end, to measure both the presence and the impact of the residual disease on the immune system. Added to this, in parallel, is the fine measurement of the degree of reconstitution of the immune repertoire as a function of the treatment of the patient: by virtue of this type of test, it is possible to rationally evaluate the overall degree of immunodeficiency of the patient and to correlate it with the level of infectious risk. 
     This method is therefore advantageous in several respects:
         Facilitating patient classification.   Diagnosing and characterizing a B or T clone through the name of the V-J rearrangement thereof, in particular by simultaneously analyzing all the T and B lymphocyte repertoires.   Providing a prognosis for the progression of a pathological condition according to the V-J clone(s) involved in the pathological condition.   Monitoring the residual disease and making a comparison with the V-J combinatorial diversity.   Refining the monitoring of the progression of patients who have lymphocytosis.   Comparing the pathological condition between various sample sources: blood, spleen, lymph node, and endeavoring to specify, if possible, “the origin of the pathological condition” by quantifying the presence of the V-J clone between these various populations.   Moving toward a correlation of the infectious risk with the lympocyte count/diversity (LCD) level of each patient.       

     EXAMPLE 14 
     Distribution of Patients According to Their TCR/Ig Diversity and Their Count 
       FIG. 14  shows a three-dimensional representation of the LCD (lymphocyte count/diversity). This graph groups together the measurement of diversity of the B lymphocytes and T lymphocytes, and also the count, as % or as absolute value, of the number of lymphocytes present in the sample. 
     The responding patient goes from a zone at risk (with a high count (approximately 80%), a low IgH diversity (8%) and a medium or even low diversity for the TCR (44%)) to a zone at lower risk, close to the PBMC samples (healthy control), with a decrease in the count(20%), and reconstitution of the IgH diversity (75%),the TCRb diversity (75%) and the TCRg diversity (90%). 
     Conversely, a nonresponding (NR) patient remains in the zone at risk and undergoes an overall immunosuppression (decrease in the count, which does not result from the efficacy of the treatment, contrary to what the clinician might believe if he or she looked only at this marker), and a decrease in the IgH, TCRb and TCRg repertoire. 
     This illustrates the paradox of the count, sole use of which can result in interpretation errors. Specifically, it is important to note that the lymphocyte count between these two samples does not change in the same way as the diversity of the combinatorial repertoire. It is therefore particularly advantageous to couple the count information and the repertoire diversity information in order to judge the real state of health of the patient. Specifically, in the present case, the leukocyte count goes from 78% to 21%, whereas the V-J combinatorial diversity goes from 8% to 75%. This approach makes it possible to verify, in a single step, and less expensively, that the patient in question has benefited from a good degree of reconstitution of the immune repertoire and that there is less risk of said patient experiencing an infectious disease. It should be noted that this is coherent with the decrease in CD19/CD5 cells indicating the presence of LCC, which goes from 84% to 4%. 
     EXAMPLE 15 
     Dynamic Immunomonitoring From Initial Diagnosis to Monitoring of a Stem Cell Transplant 
       FIG. 15  presents, in diagrammatic form, the application of the method of the invention to the monitoring of the reconstitution of the immune repertoire in a patient having undergone a stem cell (marrow) transplant. 
     Step 1: Measurement of the immune diversity, initial diagnosis, detection of the clone(s) of T cells or of B cells (darker clones). 
     Step 2: Evaluation of the efficacy of the treatment. 
     Step 3: Monitoring of the residual disease. 
     Step 4: Evaluation of the preparation of the repertoire of the recipient patient (conditioning of the transplant). 
     Step 5: Measurement of the reconstitution of the V-J diversity of the patient and early diagnosis in the event of GVHD (graph versus host disease). 
     Step 6: Evaluation of the efficacy of the treatment. 
     Step 7: Monitoring of the residual disease. 
     The longitudinal study of a patient by means of the method represented here allows a personalized treatment suitable for each situation. 
     The result of the test presented here makes it possible to measure the degree of severity of the disease and to be as sure as possible that the treatment is effective, by avoiding treating patients who would be non-responders to the treatment. The immune repertoire is here used as a general biomarker of the state of health of an individual. It is used on two levels: 1/for evaluating the patient&#39;s infectious risk, 2/while at the same time monitoring in a resolvent manner any T or B lymphocyte clones that may be the signature of a pathological condition. By virtue of a longitudinal study carried out on successive blood samples taken from a patient, it is thus possible to monitor the level of the immune repertoire throughout the treatment in order to be sure that the latter has indeed been effective and that the patient conserves a diversified immune repertoire in order to defend himself or herself against bacterial or viral infections. This dynamic diagnosis allows the clinician to adapt the treatment to his or her patient as well as possible, by proposing said patient the appropriate medicament at the correct dose and at the correct time. 
     Another advantage of the principle of the prior diagnostic test is to avoid giving too much treatment to a “responding” patient for whom the treatment at the minimum dose is effective. 
     EXAMPLE 16 
     Monitoring of an Ex Vivo Treatment Against GVHD 
     The four mappings in  FIG. 16  illustrate steps 5 and 6 of the previous figure. The four mappings represent the diversity of the immune repertoire measured using samples from the same patient at two times before the treatment (approximately 200 and 250 days), and two times post-treatment (approximately 300 and 600 days). The results concerning these four samples are represented according to the intensity, the count and the diversity. 
     1. The decrease in the diversity of the repertoire corresponds well to the appearance of a clone. The ex vivo treatment appears to have inhibited the clonal expansion (which represents close to 10% of the combinatorial repertoire monitored). The intensity corresponding to this rearrangement is systematically greater than the average intensity of the rearrangements. 
     2. The proportion of lymphocytes in the PBMCs (count) reaches its maximum around D300, and then decreases slightly around D600. 
     3. The degree of combinatorial diversity follows a reverse tendency. The increase in the proportion of T lymphocytes does not correspond to an increase in the diversity. Contrary to what would be expected, the diversity decreases between point 1 and point 2. 
     The ex vivo treatment appears to have reversed the tendency. The reconstitution takes place in two phases: the repertoire rapidly recovers a degree of diversity of 35% around D300, and then the reconstitution is slower and reaches approximately 40% around D600. 
     These results therefore show a repertoire at the periphery that is initially restricted in comparison with positive controls on a healthy thymus repertoire and on four healthy donors. The use of the method of the invention makes it possible to measure that, after D600, the degree of reconstitution of the TCR repertoire is close to that of the healthy donors. This approach therefore makes it possible to evaluate the efficacy of a treatment and to see its impact on the immune reconstitution kinetics. Finally, the use of the method of the present invention made it possible to verify that the profile of the combinatorial repertoire of the donors could be conserved on a long-term basis in the recipient, hence the fact that more systematic attention should be given to the analysis of the repertoire of donors in order to explain the change in an allograft over time. 
     The method presented here is therefore a particularly advantageous tool for clinicians who perform bone marrow grafts, since it makes it possible, inter alia, to describe and monitor clonal expansions corresponding to a Graft Versus Host (GVH) in the recipient. It also makes it possible to obtain better monitoring of the reconstitution of the repertoire post-bone-marrow-graft. The clinician will then be able to adjust the treatment in a personalized manner, by measuring the GVH/GVL ratio with greater finesse by virtue of the monitoring of the V-J combinatorial diversity. 
     EXAMPLE 17 
     Development of Humanized Transgenic Animals (Having a Human Immune Repertoire) 
     The results are presented in  FIG. 17 . 
     The present method makes it possible to evaluate, with the human TRB ImmunTraCkeR kit, the quality of reconstitution of the immune repertoire of a “humanized” transgenic mouse. In this example, the biological sample studied is derived from the spleen of an “immunodeficient mouse” (which does not have immune cells), having received an injection of CD34+ cells. These cells have the ability to diversify and to reconstitute an immune system. The method makes it possible to represent the diversity of the V-J repertoire in a two-dimensional graph. Each histogram corresponds to a V family and, within a histogram, the subdivisions correspond to a given J gene. The lowest subdivision of each histogram corresponds, in this example, to J2.7 and the highest corresponds to J1.1. It is possible to screen the “humanized” mice having an immune repertoire that is completely reconstituted (graph on the right), from the mice having a well-diversified repertoire (graph in the center), with a distribution of rearrangements that is close to that observed in a sample of human PBMC (graph on the left). 
     EXAMPLE 18 
     Use of the Method as a Tool for Screening Molecules In Vitro 
     The study represented by  FIG. 18  shows the evaluation of the effectiveness of an epitope (an antigen) in the case of the development of a treatment (vaccine), by measuring the decrease in diversity of the immune repertoire of a sample containing T lymphocytes. It is shown that, the more the diversity decreases, the greater the selection of the epitope-specific lymphocytes. 
     In this figure, three cases are represented: 
     A: The epitope tested results in a considerable lymphocyte selection, as indicated by the decrease in the diversity. 
     B: The epitope tested is not very selective, as can be observed by comparison with a negative control. 
     C: Negative control. 
     This epitope screening test makes it possible to identify the epitopes that stimulate the immune repertoire. It is possible to correlate the number of peaks (number of T clones) with the efficiency of selection and of activation of the immune repertoire. 
       FIG. 18  is derived from a qualitative and quantitative study of the murine TCRbeta repertoire using genomic DNA. By using the primers described in example 21 below (mouse TRB ImmunTraCkeR kit) to obtain the measurement of the mTRBV-J combinatorial diversity and of the intensity and the homogeneity of the repertoire, it is possible to evaluate, on this animal model, the efficacy of various vaccine protocols. 
     In another case of evaluation of the effectiveness of an epitope, illustrated by  FIG. 18 , the model for which the T repertoire is studied corresponds to an in vitro culture of lymphocytes. In this case, the study of the diversity of the T repertoire on samples of gDNA, originating from an in vitro lymphocyte culture, makes it possible to measure the clonal expansion of certain TCR alpha, beta, gamma and delta and hIgH genes following antigen presentation by presenting cells. 
     Of course, in addition to the selection of the antigen for inducing a selective immune response, there is the ability to identify the best method of injection (injection number and frequency, injection site and dose). 
       FIG. 18  illustrates another use of the method presented herein. Specifically, the epitope selection can be an undesired event during the development of new therapeutic approaches. In this case, it is important to evaluate the immunotoxicity (immunotoxicology) in order to eliminate the proteins which induce an unexpected activation of the immune system. This makes it possible to screen molecules, such as monoclonal or polyclonal antibodies for therapeutic purposes, so as to be sure that they do not induce an inappropriate lymphocyte activation. 
     Thus, the method presented herein is a particularly advantageous tool for preclinical and clinical research, as a tool for evaluating new therapeutic, and in particular vaccine, approaches. Whether on cells in culture, in the animal model or in humans, the object of the tool thus described is to provide a verdict on the quality of the expected impact on the immune system, either through a specific activation or through an absence of activation. 
     By extension, it is possible to perform quality control on the immune repertoire by monitoring one or more clone(s) characterized for study models or for production of lymphocyte cultures before reinjection (for therapeutic purposes), for example. 
     EXAMPLE 19 
     Comparison With Other Existing Technologies 
       FIG. 19  shows the summary of the results describing the comparison of various techniques for immunomonitoring of the immune cell repertoires. Various samples were studied by each of the techniques. The cell samples were treated in a controlled manner in order to prevent any bias due to the preparation of the sample. 
     Two samples called “Thymus”, corresponding to thymus-derived cells, were tested. The thymus is the organ where the maturation and selection of certain immune cells takes place. These samples are chosen since they are made up of a diversified repertoire not representing clonality, with numerous immune cells having various rearrangements (polyclonality) being present. 
     Two other samples were chosen to represent a cell population much less diverse than for thymus samples: the “Jurkat” sample which corresponds to the Jurkat cell line (monoclonality) and also the “T-line pool” sample which corresponds to a mixture, in known proportions, of three cell lines (oligoclonality). Finally, a sample called “C(−)” corresponds to a negative control, which is a cell mixture that does not comprise immune cells. 
     In addition to the present method with the human TRB “ImmunTraCkeR” kit in accordance with the invention, two techniques which make it possible to provide various pieces of information on the quality of the immune repertoire were studied. Firstly, the “Iotests” cell test (the company Beckmann Coulter), which is based on Vbeta-repertoire antigen recognition, using flow cytometry, by means of a kit of specific antibodies; this test makes it possible to identify the presence of 72% of families and 59% of the V members. Secondly, a “Biomed-2” molecular biology test (Biomed-2 European consortium), which is based on multiplex PCR approaches according to a principle different than the present invention, which makes it possible to identify whether there is a very highly represented clone in a given sample. 
     The analysis of the results observed makes it possible to identify that the “ImmunTraCkeR” test makes it possible to identify, in real-time PCR measurement, whether the sample is clonal (“Jurkat”), oligoclonal (“T-line pool”) or polyclonal (“Thymus”). The analysis also shows that analysis of the amplicons (rearrangements amplified according to the “ImmunTraCkeR” method) makes it possible to observe precisely which clones are present in terms of Vx-Jy rearrangement, without a sequencing step, whether for the “Jurkat”, oligoclonal (“T-line pool”) or polyclonal (“Thymus”) sample. The representativeness of the diversity of the combinations observed is given as a percentage (relative to a theoretical diversity where 100% of the Vx-Jy rearrangements would be observed). 
     The “Biomed-2” test clearly makes it possible to identify the very predominant presence of a clone in the sample. The “Biomed-2” test does not make it possible to distinguish between the presence of one or of a few clones if this case occurs, and this test will have a signature showing that the sample is clonal even if there is oligoclonality (“T-line pool”): the test is positive (“On”) in the two cases. 
     The “Iotests” test, which is a test carried out using fresh cells, makes it possible to distinguish clonality from oligoclonality and from polyclonality. However, unlike the “ImmunTraCkeR” test, only the Vbeta segments are studied. In addition, since the Vbeta antibodies are not exhaustive in the antibody kit of this test, the V4 rearrangement is not observed, whereas it is observed with the “ImmunTraCkeR” test. 
     The results of this study presented in  FIG. 19  show that the “ImmunTraCkeR” test has a greater technical capacity than the other two tests evaluated for analyzing immune repertoires and that, consequently, this test enables a more extended study of immune repertoires. 
     EXAMPLE 20 
     Protocol for Production of hTCRB Tests 
     In order to use the method which is described in this document, and to carry out analyses with one of the “ImmunTraCkeR” kits under good conditions, in addition to monitoring the steps for carrying out the test (presented in  FIG. 20 ), it is preferable to have produced the test by following a production protocol and according to good production practice. 
     In order to carry out a controlled production of kits for performing hTRbeta tests (or human TRbeta “ImmunTraCkeR” kit), it is necessary to be sure that the individual who must carry out production of the test for use, ultimately, in a study on samples, adheres to the various steps stated hereinafter according to the desired use. 
     Production of 12 hTRBeta tests 
     Preparation of the “oligo mix” 
     Preparation of the material 
     One Greiner plate (support) 
     Three 8-well arrays+stoppers 
     Microtubes of 0.5 mL and 1.5 mL 
     Pipettes, tips 
     Sterile H 2 O 
     EB 
     Dilution of the VPs: 
     100 μM to 20 μM 
     Calculation: 20 × Vf/100=Vi 
     Therefore, in a 0.5 mL microtube: Vi μL of oligo at 100 μM+(Vf−Vi) of EB. 
     20 μM to 3.5 μM 
     Calculation of the volume necessary for the production of 12 kits+10%: 12*1.67=20.04+10%=22 μL 
     Calculation: 3.5×22/20=3.86 μL 
     Therefore, in a 0.5 mL microtube: 3.85 μL of oligo at 20 μM+18.15 μL of H 2 O 
     Dilution of bc1do2 &amp; 2S7do1: 
     100 μM to 20 μM 
     Calculation: 20 × Vf/100=Vi 
     Therefore, in a 0.5 mL microtube: Vi μL of oligo at 100 μM+(Vf−Vi) of EB. 
     20 μM to 3.5 μM 
     Calculation of the volume necessary for the production of 12 kits+10%: 23*12*1.67=461+10%=507.1 μL 
     Calculation: 3.5×507.1/20=88.74 μL 
     In a 1.5 mL Eppendorf tube: 88.74 μL of oligo at 20 μM+418.36 μL of H 2 O 
     Distribution of the oligos Bc1do2 &amp; 2S7do1 
     Pool of Bc1do2 and 2S7do1 diluted to 3.5 μM in a sterile hemolysis tube. 
     Distribute 44.1 μL of this pool into each 0.5 mL microtube containing the diluted Vβs. 
     Mix by drawing up and down, vortex vigorously and then centrifuge briefly. 
     Distribution of oligos VP-Bc1do2-2S7do1 
     Distribute 66 μL of the “VP-Bc1do2-2S7do1” mix into the 8-well arrays, maintaining the following Vβ order: 
     Array n°1: Vβ2up2, Vβ3up2, Vβ4up_ex, Vβ5pool, Vβ6pool, Vβ7pool, Vβ9up_ex, Vβ10pool 
     Array n°2: Vβ11up_ex, Vβ12pool, Vβ13up1, Vβ14up_ex, Vβ15up_ex, Vβ16up1, Vβ18up1, Vβ19up2 
     Array n°3: Vβ20-1up_ex, Vβ24up_ex, Vβ25up_int, Vβ27up2, Vβ28up_G, Vβ29up_G, Vβ30up1 
     Preparation of the Kits 
     Preparation of the material 
     Three Greiner plates (support) 
     3*12 8-well arrays+stoppers 
     Pipettes, tips 
     Production of 12 Tests 
     Using the multichannel pipette, 5 μL of mix of arrays 1 to 3 (vol/well=64 μL) are distributed into each well of the corresponding 12 arrays. 
     For a batch of n tests, at least two tests will be used to control the quality and the conformity of the production. Among the various controls performed throughout the production so as to enable traceability and control of any drifting on a batch, the functional controls which make it possible to verify the quality before validation of the batch are important. In this respect,  FIG. 21  proposes examples on three samples of control of a test derived from a production batch. These three samples are those on which a systematic control is carried out during productions. The results are systematically compared with the preceding results in order to identify any difference. Each new result makes it possible to refine the tendency and the acceptable upper and lower limits for it to be possible for the tests to be used in a study of immune repertoire. 
       FIG. 21  represents, from top to bottom, the expected result for a thymus immune repertoire (polyclonality), an immune repertoire when the sample comprises only one very predominant clone (clonality) and, finally, an immune repertoire when the sample comprises several clones (oligoclonality). 
     The protocol above can be adapted for producing mouse TRB tests with the kit of oligonucleotides as described in example 21 hereinafter, and also for any other test production. 
     EXAMPLE 21 
     Application of the Method to the Analysis of the TRB Locus in Mice 
     The protocols and methods described in the present text can be adapted to the study of the murine TRB repertoire, using the primers described in the table below. 
     
       
         
           
               
               
               
               
               
               
               
             
               
                 TABLE 15 
               
               
                   
               
             
            
               
                   
                   
                   
                 Distance 
                   
                   
                   
               
               
                   
                   
                   
                 with the 
                   
                   
                   
               
               
                   
                 Oligo- 
                   
                 end of the 
                   
                   
                 Oligo- 
               
               
                 Name 
                 nucleotide 
                 Size 
                 V gene in 
                   
                 SEQ 
                 nucleotide 
               
               
                 of gene 
                 name 
                 (nt) 
                 bp 
                 Sequence 
                 ID No 
                 orientation 
               
               
                   
               
               
                 TRBV1 
                 mTRBV1up1 
                 23 
                 153 
                 GTGGCTGTTCACTCTGCGGAGTC 
                  99 
                 SENSE 
               
               
                 TRBV2 
                 mTRBV2up1 
                 28 
                 135 
                 TCAAAAACTTATGGACAATCAGACTGCC 
                 100 
                 SENSE 
               
               
                 TRBV3 
                 mTRBV3up1 
                 26 
                 292 
                 CAGGACCCAAAGTCTTACAGATCCCA 
                 101 
                 SENSE 
               
               
                 TRBV4 
                 mTRBV4up1 
                 25 
                 124 
                 TTGTAAACGAAACAGTTCCAAGGCG 
                 102 
                 SENSE 
               
               
                 TRBV5 
                 mTRBV5up1 
                 24 
                 227 
                 TTGGAATGTGAGCAACATCTGGGA 
                 103 
                 SENSE 
               
               
                 TRBV12 
                 mTRBV12up1 
                 25 
                 105 
                 CCCAGCAGATTCTCAGTCCAACAGT 
                 104 
                 SENSE 
               
               
                 TRBV13 
                 mTRBV13up1 
                 22 
                 287 
                 TGGAGGCTGCAGTCACCCAAAG 
                 105 
                 SENSE 
               
               
                 TRBV14 
                 mTRBV14up1 
                 28 
                 130 
                 GTTATAGATAATTCACAGTTGCCCTCGG 
                 106 
                 SENSE 
               
               
                 TRBV15 
                 mTRBV15up1 
                 24 
                 362 
                 TTCCGTGTTCATAACTCCACAGCG 
                 107 
                 SENSE 
               
               
                 TRBV16 
                 mTRBV16up1 
                 23 
                  62 
                 CTGAAGATCCAGAGCACGCAACC 
                 108 
                 SENSE 
               
               
                 TRBV17 
                 mTRBV17up1 
                 25 
                 108 
                 TTTTGAGAAGTTCCAATCCAGTCGG 
                 109 
                 SENSE 
               
               
                 TRBV19 
                 mTRBV19up1 
                 27 
                 113 
                 CGATCTATCTGAAGGCTATGATGCGTC 
                 110 
                 SENSE 
               
               
                 TRBV20 
                 mTRBV20up1 
                 25 
                 199 
                 CTGTAGCTTGGTATCGTCAATCGCC 
                 111 
                 SENSE 
               
               
                 TRBV23 
                 mTRBV23up1 
                 27 
                 376 
                 AACACACCCAAATAATTTTCCTTGCTG 
                 112 
                 SENSE 
               
               
                 TRBV24 
                 mTRBV24up1 
                 27 
                  61 
                 TGGAAATCCTATCCTCTGAAGAAGACG 
                 113 
                 SENSE 
               
               
                 TRBV26 
                 mTRBV26up1 
                 24 
                 395 
                 TCTTTGACCTGGAGATTGCCAACC 
                 114 
                 SENSE 
               
               
                 TRBV29 
                 mTRBV29up1 
                 24 
                  99 
                 ATACAGGGTCTCACGGAAGAAGCG 
                 115 
                 SENSE 
               
               
                 TRBV30 
                 mTRBV30up2 
                 23 
                 155 
                 ATGGCAACTGCAAATGAAGGCTC 
                 116 
                 SENSE 
               
               
                 TRBV31 
                 mTRBV31up1 
                 24 
                  73 
                 ACGACCAATTCATCCTAAGCACGG 
                 117 
                 SENSE 
               
               
                   
               
               
                   
                   
                   
                 Distance 
                   
                   
                   
               
               
                   
                   
                   
                 with the 
                   
                   
                   
               
               
                   
                 Oligo- 
                   
                 start of the 
                   
                   
                 Oligo- 
               
               
                 Gene 
                 nucleotide 
                 Size 
                 J gene in 
                   
                   
                 nucleotide 
               
               
                 name 
                 name 
                 (bp) 
                 bp 
                   
                   
                 orientation 
               
               
                   
               
               
                 TRBJ1.7 
                 mTRBJ1.7do1 
                 26 
                 2315 
                 GCATGGCTATTTGAAACAGTGGCTCT 
                 118 
                 ANTISENSE 
               
               
                 TRBJ2.7 
                 mTRBJ2.7do1 
                 22 
                  241 
                 CCTTGTCCTGGCTTGCGAGAGA 
                 119 
                 ANTISENSE 
               
               
                   
               
            
           
         
       
     
     EXAMPLE 22 
     Examples of Results Obtained by Quantitative PCR Analysis of the Combinatorial Immune Repertoire on Genomic DNA 
     The use of quantitative PCR according to the invention makes it possible to rapidly classify a patient in one of the following three categories: healthy (as regards the condition of said patient&#39;s immune system), lymphoproliferation or lymphopenia. Real-time PCR makes it possible to have results in 2-3 hours instead of 5 hours for an analysis by “non-real-time” PCR requiring migration of the amplification products. Ultimately, this increase in speed of return will make it possible to carry out health monitoring on patients. 
     The three situations are illustrated in  FIGS. 22A-22B .  FIG. 22A  presents a diagram of the three separate situations;  FIG. 22B  presents a summarizing diagram of the three situations. N.B. other than for the control gene (in this example, the Actin gene), each curve corresponds to the PCR amplification of the sum of the rearrangements of a given V gene with all the J genes monitored. 
     The first situation (sample A) is that of a “healthy” individual, where all the amplifications are detected grouped together, in a Ct range of less than five cycles, this being the case between two and six cycles after the detection of the housekeeping gene. 
     The second diagram of  FIG. 22A  is characteristic of a “lymphoproliferation” (sample B), where at least one amplification of a V gene is detected earlier than the group of the other curves (which corresponds to a monoclonality if one curve “emerges” before the others, and to an oligoclonality if it is the case of a few curves). Depending on the degree of lymphoproliferation, this (or these few) curve(s) will be more or less close to the curve of the Actin gene (the greater the degree of lymphoproliferation, the closer said curve(s) will be; the detection may even be observed before the housekeeping gene); conversely, the detection of the other rearrangements will occur later when the degree of lymphoproliferation is greater (the curves are therefore shifted to the right). Observation: if the lymphoproliferation is monoclonal, the amplification of the corresponding rearrangement may be detected at the same time as the actin (in certain cases, in particular if the amplification efficiency of the corresponding primers is greater than that of the pair of primers for the actin gene, this detection might be before the actin). If the lymphoproliferation is monoclonal, the other rearrangements will be virtually undetected, or be detected after a high cycle number (more than five cycles after the detection of the predominant rearrangement). 
     In the event of early detection of a rearrangement not present among the ten rearrangements normally most represented, there is a suspicion of clonality, and it is necessary to monitor the patient in order to confirm or refute this risk. 
     The third diagram of  FIG. 22A  represents a case of “lymphopenia” (sample C): despite detection of the control gene (for example, actin) at a cycle number similar to the healthy individuals, demonstrating a comparable amount of gDNA and an absence of PCR inhibition, the detection of the rearrangements is very late. This is the sign of a very small presence of rearrangements, which shows that there are very few lymphocytes in the sample. 
     EXAMPLE 23 
     Interpretation of the Results Obtained by QPCR 
     Direct Identification, by Quantitative PCR, of a Lack of Lymphocyte Diversity Associated With a Lymphopenia 
     The inventors defined two novel indices for interpreting the results obtained by means of the methods according to the invention, in particular for identifying a lack of lymphocyte diversity, in particular associated with a lymphopenia. 
     The first index, referred to herein as “divpenia ratio”, is calculated in the following way: 
       “divpenia ratio”=[cycle of emergence of the actin quality control]/[mean (or median) of the cycles of emergence of the  V  rearrangements of the sample].
 
     Of course, this index, the objective of which is to easily identify a lack of diversity, can be adapted by those skilled in the art to any control gene other than actin. In the present case, a ratio of less than 0.78, and more particularly less than 0.74 (measured by QPCR), is an indicator of a low combinatorial immune diversity (situation described herein as “divpenia”). 
     This index, measured in the three situations presented in example 22 above, gives the following results:
         Sample A “Normal”       

       “divpenia ratio”=20 cycles ( Ct  Actin)/Mean (or median) rearrangements 25 cycles=0.80.
         Sample C “Lymphopenia”       

       “divpenia ratio”=20 cycles/28 cycles=0.71.
 
     Other means of identifying a lymphopenia by QPCR: in the case where the two samples show detection of the control gene at the same number of cycles, another means of identifying a lymphopenia is to directly subtract the mean of the number of cycles for detection of the rearrangements of a sample of a “healthy” individual from the mean of the individual tested. In this example, between sample A (healthy) and sample C, a difference in the mean Cts of 28−25=3 cycles of mean difference is observed, i.e. approximately 2 3 =8 times less signal detected on average in the lymphopenic patient. 
     Identification of a Lymphoproliferation Directly by QPCR 
     In a given sample, lymphoproliferation (of a lymphocyte) is associated with increased detection of the corresponding V-J rearrangement. In QPCR this consists in detecting the corresponding V gene from a very low number of QPCR cycles onward. The greater the lymphoproliferation of this lymphocyte, the greater the proportion of the sample represented by the lymphocyte. As a result, the detection of the corresponding rearrangement takes place at a cycle number close to the Actin gene (or even before, cf. observation in example 22). Conversely, the other rearrangements of the sample are less frequent and their detection requires a greater number of QPCR cycles. In the end, this results in an increase in the difference between the Cts corresponding to the detection of the first and of the last rearrangements detected. If this difference (delta Ct) is greater than n cycles, this indicates the presence of a lymphoproliferation, which is all the greater, the larger this delta is. 
     This approach therefore makes it possible to detect the presence of a lymphoproliferation by QPCR and characterize the name of the V family involved. To identify the V-J rearrangement, it is sufficient to subsequently migrate the QPCR products and to characterize it according to the expected size. 
     N.B. given knowledge of the list of the ten TRB rearrangements predominantly detected in the PBMCs, it is also possible, in certain cases, to have suspicions of “emerging” clonality if families of TRBV genes not present in this list are detected. 
       *Δ Ct  index=[ Ct max]−[ Ct min] for a sample.
 
     In practice, it is considered that there is no lymphoproliferation if ΔCt&lt;6 cycles and that a ΔCt index &gt;6 cycles indicates lymphoproliferation of a clone, which then represents at least 10% of the lymphocytes of the sample.
         Samples A and C:       

       Δ Ct= 27−24=3 cycles.
         Sample B:       

     ΔCt=30−23=7 cycles, which clearly indicates a lymphoproliferation. 
     N.B. it is preferable to use a ratio for measuring the lack of diversity and a difference in Ct for identifying a clone, or vice versa, in order to avoid errors and to be able to work in a standardized manner with respect to the amount of genomic DNA of the sample, which is measured by detection of the control gene (housekeeping gene or the like). 
     The table below describes the detection, by quantitative PCR, of the cycles for emergence (Ct) of the first ten V genes detected, on three different PBMC samples. This table gives the Ctmax (last PCR product detected), the Ctmin (rearrangement detected first), the Delta Ct between Ctmax and Ctmin, the median of the Cts of the sample (excluding CQ actin) the mean of the Cts of the sample (excluding Ct Actin), the “divpenia” ratio between Ct Actin and the median or the mean of the Cts. 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 PBMC Per 
                   
                   
                   
                   
               
               
                 Genes 
                 Ct cycles 
                 Indices 
                 Value 
                 Interpretation 
               
               
                   
               
               
                 QC Actin 
                 22.02 
               
               
                 BV4 
                 24.18 
               
               
                 BV24 
                 24.28 
                 CtMax 
                 29.32 
               
               
                 BV20 
                 24.46 
                 CtMin 
                 24.18 
               
               
                 BV27 
                 24.56 
                 Delta Ct Max-Min 
                 5.14 
                 Very low risk of 
               
               
                   
                   
                   
                   
                 lymphoproliferation 
               
               
                 BV6 
                 24.7 
               
               
                 BV5 
                 25.53 
                 Median Ct 
                 26.13 
               
               
                 BV7 
                 25.72 
                 divpenia ratio [Ct 
                 0.842709529 
                 Low risk of 
               
               
                   
                   
                 actin]/[Median Ct] 
                   
                 divpenia 
               
               
                 BV30 
                 25.95 
                 Mean Ct 
                 26.29 
               
               
                 BV12 
                 26 
                 divpenia ratio [Ct 
                 0.837580829 
                 Low risk of 
               
               
                   
                   
                 actin]/[Mean Ct] 
                   
                 divpenia 
               
               
                 BV15 
                 26.07 
               
               
                   
               
               
                 BBMC Br 
               
               
                 Genes 
                 Ct cycles 
                 Indices 
                 Value 
                 Interpretation 
               
               
                   
               
               
                 QC Actin 
                 19.99 
               
               
                 BV20 
                 23.7 
               
               
                 BV6 
                 24.17 
                 CtMax 
                 28.5 
               
               
                 BV5 
                 24.26 
                 CtMin 
                 23.7 
               
               
                 BV24 
                 24.48 
                 Delta Ct Max-Min 
                 4.8 
                 Very low risk of 
               
               
                   
                   
                   
                   
                 lymphoproliferation 
               
               
                 BV7 
                 24.59 
               
               
                 BV27 
                 24.63 
                 Median Ct 
                 25.27 
               
               
                 BV7 
                 24.65 
                 divpenia ratio [Ct 
                 0.791056589 
                 Low risk of 
               
               
                   
                   
                 actin]/[Median Ct] 
                   
                 divpenia 
               
               
                 BV30 
                 24.7 
                 Mean Ct 
                 25.54 
               
               
                 BV12 
                 24.72 
                 divpenia ratio [Ct 
                 0.782693814 
                 Low risk of 
               
               
                   
                   
                 actin]/[Mean Ct] 
                   
                 divpenia 
               
               
                 BV15 
                 24.93 
               
               
                   
               
               
                 PBMC SH 
               
               
                 Genes 
                 Ct cycles 
                 Indices 
                 Value 
                 Interpretation 
               
               
                   
               
               
                 QC Actin 
                 23.45 
               
               
                 BV20 
                 23.51 
               
               
                 BV6 
                 23.77 
                 CtMax 
                 27.56 
               
               
                 BV4 
                 23.83 
                 CtMin 
                 23.51 
               
               
                 BV5 
                 24.54 
                 Delta Ct Max-Min 
                 4.05 
                 Very low risk of 
               
               
                   
                   
                   
                   
                 lymphoproliferation 
               
               
                 BV30 
                 24.72 
               
               
                 BV28 
                 24.91 
                 Median Ct 
                 25.79 
               
               
                 BV7 
                 24.98 
                 divpenia ratio [Ct 
                 0.909267158 
                 Low risk of 
               
               
                   
                   
                 actin]/[Median Ct] 
                   
                 divpenia 
               
               
                 BV27 
                 24.98 
                 Mean Ct BV 
                 25.73 
               
               
                 BV9 
                 25.32 
                 detection divpenia ratio [Ct 
                 0.911387485 
                 Low risk of 
               
               
                   
                   
                 actin]/[Mean Ct] 
                   
                 divpenia 
               
               
                 BV24 
                 25.45 
               
               
                   
               
            
           
         
       
     
     The following table illustrates the detection of a lymphoproliferation and the appearance of an associated lack of diversity (“divpenia”): each analysis is carried out at a constant amount of gDNA (50 ng of gDNA per PCR reaction), on samples composed of a distribution of PBMCs diluted, respectively, in 10%, 50%, 80% and 100% of T SUP cell lines (having a TRBV9 rearrangement). 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 PBMC 90% + SUP 10% 
                   
                   
                   
                   
               
               
                 Gene 
                 Ct 
                 Index 
                 Value 
                 Interpretation 
               
               
                   
               
               
                 CQi 
                 22.96 
               
               
                 BV9 
                 23.75 
               
               
                 BV5 
                 26.2 
                 CtMax 
                 30.47 
               
               
                 BV20 
                 26.2 
                 CtMin 
                 23.75 
               
               
                 BV6 
                 26.5 
                 Delta Ct Max-Min 
                 6.72 
                 Moderate risk of 
               
               
                   
                   
                   
                   
                 lymphoproliferation 
               
               
                 BV27 
                 26.67 
               
               
                 BV4 
                 26.69 
                 Median Ct 
                 27.85 
               
               
                 BV3 
                 26.84 
                 Divpenia ratio [Ct 
                 0.824416517 
                 Low risk of divpenia 
               
               
                   
                   
                 actin]/[Median Ct] 
               
               
                 BV19 
                 27.07 
                 Mean Ct 
                 27.66695652 
               
               
                 BV30 
                 27.11 
                 Divpenia ratio [Ct 
                 0.829870824 
                 Low risk of divpenia 
               
               
                   
                   
                 actin]/[Mean Ct] 
               
               
                 BV24 
                 27.53 
               
               
                 BV2 
                 27.71 
               
               
                 BV12 
                 27.85 
               
               
                 BV10 
                 27.98 
               
               
                 BV18 
                 28.04 
               
               
                 BV11 
                 28.09 
               
               
                 BV29 
                 28.11 
               
               
                 BV7 
                 28.12 
               
               
                 BV14 
                 28.44 
               
               
                 BV25 
                 28.6 
               
               
                 BV15 
                 29 
               
               
                 BV28 
                 29.38 
               
               
                 BV13 
                 29.99 
               
               
                 BV16 
                 30.47 
               
               
                   
               
               
                 PBMC 50% + SUP 50% 
               
               
                 (clone of TRBV9) 
               
               
                 Gene 
                 Ct 
                 Index 
                 Value 
                 Interpretation 
               
               
                   
               
               
                 CQi 
                 23.03 
               
               
                 BV9 
                 22.12 
               
               
                 BV5 
                 24.54 
                 CtMax 
                 30.77 
               
               
                 BV20 
                 24.55 
                 CtMin 
                 22.12 
               
               
                 BV19 
                 25.73 
                 Delta Ct Max-Min 
                 8.65 
                 High risk of 
               
               
                   
                   
                   
                   
                 lymphoproliferation 
               
               
                 BV24 
                 25.84 
               
               
                 BV7 
                 26.05 
                 Median Ct 
                 27.22 
               
               
                 BV4 
                 26.36 
                 Divpenia ratio [Ct 
                 0.846069067 
               
               
                   
                   
                 actin]/[Median Ct] 
               
               
                 BV10 
                 26.69 
                 Mean Ct 
                 27.23130435 
               
               
                 BV30 
                 26.75 
                 Divpenia ratio [Ct 
                 0.845717844 
                 Low risk of divpenia 
               
               
                   
                   
                 actin]/[Mean Ct] 
               
               
                 BV11 
                 26.98 
               
               
                 BV3 
                 27.05 
               
               
                 BV27 
                 27.22 
               
               
                 BV18 
                 27.39 
               
               
                 BV12 
                 27.43 
               
               
                 BV25 
                 27.66 
               
               
                 BV6 
                 28.13 
               
               
                 BV14 
                 28.16 
               
               
                 BV29 
                 28.56 
               
               
                 BV28 
                 28.87 
               
               
                 BV13 
                 29.24 
               
               
                 BV2 
                 29.72 
               
               
                 BV16 
                 30.51 
                 . 
               
               
                 BV15 
                 30.77 
               
               
                   
               
               
                 PBMC 20% + SUP 80% 
               
               
                 (clone of TRBV9) 
               
               
                 Gene 
                 Ct 
                 Index 
                 Value 
                 Interpretation 
               
               
                   
               
               
                 CQi 
                 23.01 
               
               
                 BV9 
                 21.23 
               
               
                 BV5 
                 25.25 
                 CtMax 
                 31.1 
               
               
                 BV20 
                 25.9 
                 CtMin 
                 21.23 
               
               
                 BV24 
                 26.45 
                 Delta Ct Max-Min 
                 9.87 
                 Very high risk of 
               
               
                   
                   
                   
                   
                 lymphoproliferation 
               
               
                 BV4 
                 27.31 
               
               
                 BV6 
                 27.33 
                 Median Ct 
                 28.03 
               
               
                 BV3 
                 27.43 
                 Divpenia ratio [Ct 
                 0.820906172 
               
               
                   
                   
                 actin]/[Median Ct] 
               
               
                 BV27 
                 27.45 
                 Mean Ct 
                 27.89782609 
               
               
                 BV11 
                 27.75 
                 Divpenia ratio [Ct 
                 0.825 
                 Low risk of divpenia 
               
               
                   
                   
                 actin]/[Mean Ct] 
               
               
                 BV12 
                 27.79 
               
               
                 BV30 
                 27.89 
               
               
                 BV29 
                 28.03 
               
               
                 BV19 
                 28.09 
               
               
                 BV7 
                 28.19 
               
               
                 BV18 
                 28.38 
               
               
                 BV2 
                 28.43 
               
               
                 BV10 
                 28.82 
               
               
                 BV13 
                 29.16 
               
               
                 BV14 
                 29.21 
               
               
                 BV15 
                 29.36 
               
               
                 BV25 
                 30.27 
               
               
                 BV28 
                 30.83 
               
               
                 BV16 
                 31.1 
               
               
                   
               
               
                 PBMC 0% + SUP 100% 
               
               
                 (clone of TRBV9) 
               
               
                 Gene 
                 Ct 
                 Index 
                 Value 
                 Interpretation 
               
               
                   
               
               
                 CQi 
                 23.62 
               
               
                 BV9 
                 21.03 
               
               
                 BV5 
                 25.35 
                 CtMax 
                 34.89 
               
               
                 BV24 
                 27.06 
                 CtMin 
                 21.03 
               
               
                 BV14 
                 30.24 
                 Delta Ct Max-Min 
                 13.86 
                 Very high risk of 
               
               
                   
                   
                   
                   
                 lymphoproliferation 
               
               
                 BV18 
                 30.53 
               
               
                 BV20 
                 30.91 
                 Median Ct 
                 32.38 
               
               
                 BV10 
                 31.39 
                 Divpenia ratio [Ct 
                 0.729462631 
               
               
                   
                   
                 actin]/[Median Ct] 
               
               
                 BV11 
                 31.92 
                 Mean Ct 
                 31.53913043 
               
               
                 BV4 
                 32.1 
                 Divpenia ratio [Ct 
                 0.749 
                 High risk of divpenia 
               
               
                   
                   
                 actin]/[Mean Ct] 
               
               
                 BV12 
                 32.14 
               
               
                 BV19 
                 32.28 
               
               
                 BV6 
                 32.38 
               
               
                 BV27 
                 32.46 
               
               
                 BV15 
                 32.58 
               
               
                 BV25 
                 32.59 
               
               
                 BV2 
                 32.79 
               
               
                 BV16 
                 32.9 
               
               
                 BV7 
                 33.05 
               
               
                 BV30 
                 33.6 
               
               
                 BV13 
                 34.13 
               
               
                 BV3 
                 34.2 
               
               
                 BV28 
                 34.88 
               
               
                 BV29 
                 34.89 
               
               
                   
               
            
           
         
       
     
     EXAMPLE 24 
     Example of Results in Vaccinology: Combination of the Measurement of the Number of Regulatory T Lymphocytes and Immune Repertoire 
     This example goes deeper into what has already been presented in example 18 above. 
     By virtue of the method of the invention, the inventors were able to observe that, when an individual has an initial combinatorial diversity &gt;50%, the observation of a decrease in combinatorial diversity combined with a decrease in detection of regulatory T cells or of CD25++ cells is an indicator of the vaccination efficacy. 
     This is illustrated in  FIG. 23 , which shows a graph of the measurement of the number of regulatory T lymphocytes as a function of the immunity diversity of the T lymphocytes. Each point corresponds to an individual (the individuals in this example being mice). The graph shows three groups of individuals: A/before vaccination or injection of PBS (=negative control), B/after vaccination with vaccination protocol n°1, C/after vaccination with vaccination protocol n°2. 
     As already observed in example 18, the vaccination of mice having a normal immune diversity (&gt;70% combinatorial diversity) induces a decrease in the diversity. This decrease in the diversity is, in addition, in combination with a decrease in the number of regulatory T lymphocytes and CD4+25++ cells. In the situation presented, it is possible to distinguish differences between the two vaccination protocols in terms of their impact on the immune system. From a functional point of view, the mice suffering from cancer and having received protocol n°2 (group C) have a greater survival than the mice having received protocol n°1. These results appear to indicate that it is possible to predict the vaccine efficacy by combining the measurement of the immune diversity with the measurement of the number of regulatory T lymphocytes. This therefore makes it possible to evaluate and, optionally, to compare the efficacy of various vaccine protocols, in order to test the effect of all the factors involved, such as, for example, the nature of the adjuvant, the type of vaccine (peptides, recombinant, etc.), the dose, the method of administration and/or the site of injection, the frequency of administration, etc. 
     The overall observation of the results shows that, in general, vaccinating mice makes it possible to make the % of the populations and the diversity of the mice within the same group more homogeneous. On the graphs, this corresponds to a larger “surface area” for the PBS control groups than for the groups of vaccinated mice. This is because, for the nontreated control mice, large differences are observed both in terms of the phenotypes and in terms of the combinatorial diversity. After vaccination, the distribution of the phenotype of the lymphocyte populations studied and also the combinatorial diversity of the repertoire are more homogeneous within the same group of mice. 
     A vaccine protocol which induces a two-fold decrease in the number of regulatory T lymphocytes in a lymph node, in the spleen or at the periphery, combined with a decrease in the immune diversity of more than 10%, and preferably more than 15%, relative to the group before vaccination or to a control group, will, a priori, be an effective protocol. N.B. according to the observations made by the inventors, the greater the decrease in these two biomarkers, the greater the effect of the vaccination protocol on the immune system. The measurement of the lymphocyte diversity, combined, where appropriate, with the measurement of the number of regulatory T lymphocytes, therefore makes it possible to select a more effective vaccination protocol from various protocols. 
     Along the same lines, any strategy aimed at transiently decreasing the amount of regulatory T cells in the organism would make it possible to increase vaccine and antitumor efficacy. 
     EXAMPLE 25 
     Follow-Up of the Immunological Status in Two- and Three-Dimensional Graphs 
     The immunological status of an immunosuppressed patient was followed during the reconstitution of his immune repertoire ( FIGS. 24A-24B  and  FIG. 25 ). 
     Arrows pointing to the right and to the top (green in a colored version) show that the patient is reconstituting both the number and the diversity of his T lymphocytes ( FIG. 24A ) and of his B lymphocytes ( FIG. 24B ). 
     At D22, a decline is however observed, as shown by the arrow (red in a colored version) pointing to the left and to the bottom. This occurred after an immunosupressing treatment given to the patient at D20, after the sampling. 
     The three-dimensional graph shown in  FIG. 25  gathers the data shown in both  FIG. 24A  and  FIG. 24B . 
     This example shows that the claimed tools enable a clinician or any person in charge of caring a patient to follow, “at one glance”, the evolution of the immune status of a patient during the treatment or following a treatment. The effects of treatments on immune reconstitution can be seen quickly and easily. These graphs are useful to check that the immune markers (numeration and diversity) get closer to the general population zone which could be considered as a “healthy zone”, and hence that the patient recovers a good level of immunocompetence. 
     EXAMPLE 26 
     Follow-Up of the Immunological Status of Patients Suffering From DLBCL 
     Patients suffering from diffuse large B cell lymphoma (DLBCL) were treated by the current standard for care, especially in elderly patients, which is immunochemotherapy composed of rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (abbreviated R-CHOP). Patients received R-CHOP at D0 (J0 on  FIGS. 27A-27G ). J1C2 corresponds to the first day of the second cure; the sampling was performed before the cure. Three other measures were performed at 3 months (3M), 6 months (6M) and 18 months (18M) after the beginning of the treatment. 
       FIG. 26  illustrates the follow-up of 21 patients receiving the treatment, by the multi-n-plex technology described herein. Interestingly, 82% of the patients suffering from DLBCL and having a combinatorial TRB diversity ≦58% the first day of the second cure (J1C2) developed a febrile and/or infectious serious event, whereas this occurred in only 10% of the patients having a combinatorial TRB diversity &gt;58% the first day of the second cure. 
       FIGS. 27A-27G  show the individual evolution of 5 different patients. The occurrence of a febrile and/or infectious event is indicated by a Roman numeral corresponding to the grade of the infection. The higher the grade, the more serious the infection. Generally, an infection of grade three or more necessitates hospital admission. (N.b. When the Roman numeral is indicated besides the indication “J1C2”, this means that the infectious event occurred between D0 and the first day of the second cure, etc.). 
     Other information which can be indicated on the graph comprise the type of treatment which was administered, other associated symptoms and the like. 
     REFERENCES 
     Aude-Garcia, C., Gallagher, M., Marche, P. N., and Jouvin-Marche E. (2001). Preferential ADV-AJ association during recombination in the mouse T-cell receptor alpha/delta locus. Immunogenetics 52, 224-230. 
     Baum, P. D., and McCune, J. M. (2006). Direct measurement of T-cell receptor repertoire with AmpliCot, Nat Methods 3, 895-901. 
     Baum, T. P. Hierle, V., Pasqual, N., Bellahcene, F., Chaume, D., Lefranc, M. P., Jouvin-Marche, E., Marche, P. N., and Demongeot, J. (2006). IMGT/GeneInfo: T cell receptor gamma TRG and delta TRD genes in database give access to all TR potential V(D)J recombinations. BMC Bioinformatics 7, 224. 
     Baum, T. P., Pasqual, N., Thuderoz, F., Hierle, V., Chaume, D., Lefranc, M. P., Jouvin-Marche, E., Marche, P. N., and Demongeot, J. (2004). IMGT/GeneInfo: enhancing V(D)J recombination database accessibility. Nucleic Acids Res 32, D51-54. 
     Berek. C., Griffiths, G. M., and Milstein, C. (1985). Molecular events during maturation of the immune response to oxazolone. Nature 316, 412-418. 
     Bogue, M., Gilfillan, S., Benoist, C., and Mathis, D. (1992). Regulation of N-region diversity in antigen receptors through thymocyte differentiation and thymus ontogeny. Proc Natl Acad Sci USA 89, 11011-11015. 
     Bonarius, H. P., Baas, F., Remmerswaal, E. B., van Lier, R. A., ten Berge, I. J., Tak, P. P., and de Vries, N. (2006). Monitoring the T-cell receptor repertoire at single-clone resolution. PLoS ONE 1, e55. 
     Cabaniols, J. P., Fazilleau, N., Casrouge, A., Kourilsky, P., and Kanellopoulos, J. M. (2001). Most alpha/beta T cell receptor diversity is due to terminal deoxynucleotidyl transferase. J Exp Med 194, 1385-1390. 
     Chaudhuri, J., Tian, M., Khoung, C., Chua, K., Pinaud, E., and Alt, F. W. (2003). Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 422, 726-730. 
     Cochet, M., Pannetier, C., Regnault, A., Darche, S., Leclerc, C., and Kourilsky, P. (1992). Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur J Immunol 22, 2639-2647. 
     Davis, M. M., and Bjorkman, P. J. (1988). T-cell antigen receptor genes and T-cell recognition. Nature 334, 395-402. 
     Douek, D. C., McFarland, R. D., Keiser, P. H., Gage, E. A., Massey, J. M., Haynes, B. F., Polis, M. A., Haase, A. T., Feinberg, M. B., Sullivan, J. L. et al. (1998). Changes in thymic function with age and during the treatment of HIV infection. Nature 396, 690-695. 
     Fugmann, S. D., Lee, A. I., Shockett, P. E., Villey, I. J., and Schatz, D. G. (2000). The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 18, 495-527. 
     Fuschiotti, P., Pasqual, N., Hierle, V., Borel, E., London, J., Marche, P. N., and Jouvin-Marche, E. (2007). Analysis of the TCR alpha-chain rearrangement profile in human T lymphocytes. Mol Immunol 44, 3380-3388. 
     Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., and Stevenson, F. K. (1999). Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1818-1851. 
     Huang, C., and Kanagawa, O. (2001). Ordered and coordinated rearrangement of the TCR alpha locus: role of secondary rearrangement in thymic selection. J. Immunol 166, 2597-2601. 
     Jouvin-Marche, E., Aude-Garcia, C., Candeias, S., Borel, E., Hachemi-Rachedi, S., Gahery-Segard, H., Cazenave, P. A., and Marche, P. N. (1998). Differential chronology of TCRADV2 gene use by alpha and delta chains of the mouse TCR. Eur J Immunol 28, 818-827. 
     Kotani, A., Okazaki, I. M., Muramatsu, M., Kinoshita, K., Begum, N. A., Nakajima, T., Saito, H., and Honjo, T. (2005). A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc Natl Acad Sci USA 102, 1506-1511. 
     Lang. R., Pfeffer, K., Wagner, H., and Heeg, K. (1997). A rapid method for semiquantitative analysis of the human V beta-repertoire using TaqManR PCR. J Immunol Methods 203, 181-192. 
     Lefrancs,  The Immunoglobulin Facts Book  2001. 
     Lefrancs,  The T cell receptor Facts Book  2001. 
     Oprea, M., and Kepler, T. B. (1999). Genetic plasticity of V genes under somatic hypermutation: statistical analyses using a new resampling-based methodology. Genome Res 9, 1291-1301. 
     Pannetier, C., Even, J., and Kourilsky, P. (1995). T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 16, 176-181. 
     Pasqual, N., Gallagher, M., Aude-Garcia, C., Loiodice, M., Thuderoz, F., Demongeot, J., Ceredig, R., Marche, P. N., and Jouvin-Marche, E. (2002). Quantitative and qualitative changes in V-J alpha rearrangements during mouse thymocytes differentiation: implication for a limited T cell receptor alpha chain repertoire. J Exp Med 196, 1163-1173. 
     Pham, T., Belzer, M., Church, J. A., Kitchen, C., Wilson, C. M., Douglas, S. D., Geng, Y., Silva, M., Mitchell, R. M., and Krogstad, P. (2003). Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circles. Clin Diagn Lab Immunol 10, 323-328. 
     Rytkonen, M. A., Hurwitz, J. L., Thompson, S. D., and Pelkonen, J. (1996). Restricted onset of T cell receptor alpha gene rearrangement in fetal and neonatal thymocytes. Eur J Immunol 26, 1892-1896. 
     Van den Beemd, van Dongen et al. (2000), “Flow cytometric detection of clonality in mature T-cell malignancies by use of a Vb antibody kit”, ISAC Abstract. 
     Wang. F., Huang, C. Y., and Kanagawa, O. (1998). Rapid deletion of rearranged T cell antigen receptor (TCR) Valpha-Jalpha segment by secondary rearrangement in the thymus: role of continuous rearrangement of TCR alpha chain gene and positive selection in the T cell repertoire formation. Proc Natl Acad Sci USA 95, 11834-11839.